

8797, A NOVEL HUMAN GALACTOSYLTRANSFERASE AND USES THEREOF**Related Applications**

This application claims the benefit of U.S. Provisional Application Serial No. 5 60/229,829, filed August 31, 2000, the entire contents of which are incorporated herein by this reference.

Background of the Invention

Glycoproteins are glycosylated by the cotranslational addition of carbohydrates (*i.e.*, sugars) to specific amino acid residues on the protein (Imperiale *et al.* (1999) *Curr. Opin. Cell Biol.* 3:643-649). After transfer, the sugars are processed by the actions of glycosylhydrolases, which trim sugars, and glycosyltransferases, which add sugars. The glycosylation of proteins can dramatically alter the folding (*i.e.*, the structure) and, therefore, the function of the protein. This modification also serves to stabilize the protein, as well as to assist in the assembly of oligomeric complexes and the correct orientation of cell surface glycoproteins at the plasma membrane.

Glycosyltransferases are a family of enzymes which catalyze the formation of a glycosidic bond between two sugar molecules (*e.g.*, a nucleotide-bound donor sugar and an acceptor-bound acceptor sugar) (Darnell *et al.*, *Molecular Cell Biology*, Scientific American Books, Inc., 1990; Voet and Voet, *Biochemistry*, John Wiley and Sons, Inc., 1990). These enzymes have a precise specificity for substrate, donor sugar nucleotide, and acceptor. Members of this family of enzymes vary in structure, although glycosyltransferases share several characteristics. Glycosyltransferases are integral membrane proteins that possess a short amino-terminal cytoplasmic domain, a transmembrane domain, and a larger carboxy-terminal catalytic domain that typically consists of 325 or more amino acids (Natsuka *et al.* (1994) *Curr. Opin. Struct. Biol.* 4:683-691). Although most of these proteins are membrane bound, they may be proteolytically cleaved into soluble forms which may be secreted.

Glycosyltransferase sugar specificity may be directed to sugars such as galactose, glucose, fucose, or mannose, by galactosyltransferases, glucosyltransferases, fucosyltransferases, or mannosyltransferases, respectively (for a review, see the WWW Guide to Cloned Glycosyltransferases, available online through Wilson, I., Institut für Chemie der Universität für Bodenkultur, Muthgasse 18, Wein (1996)).

Galactosyltransferases are involved in lactose synthesis and transfer galactose to N-acetylglucosamine, yielding N-acetyllactosamine (Voet and Voet, *Biochemistry*, John Wiley and Sons, Inc., 1990). The transfer of galactose may be directed to a growing oligosaccharide, lipid, or protein acceptor (Breton *et al.* (1999) *Curr. Opin. Struct. Biol.* 9:563-571. These enzymes are typically found in the trans Golgi, although they may occasionally be located to the cell surface or in soluble forms in milk, amniotic fluid,

cerebrospinal fluid, saliva, urine, and serum (Axford (1999) *Biochim. Biophys. Acta* 1455:219-229). Galactosyltransferases play a multifunctional role in normal cell physiology. They are expressed in a tissue specific manner, and are regulated in healthy tissues as well as in disease states. These enzymes are present on the cell surface of sperm, 5 and play a role in mammary gland morphogenesis and lactation (Brockhausen *et al.* (1998) *Acta Anatomica* 161:36-78).

Summary of the Invention

The present invention is based, at least in part, on the discovery of novel human 10 galactosyltransferase family members, referred to herein as “human galactosyltransferase-1” or “HGT-1” nucleic acid and polypeptide molecules. The HGT-1 nucleic acid and polypeptide molecules of the present invention are useful as modulating agents in regulating a variety of cellular processes, *e.g.*, cell physiology, and/or cellular proliferation, growth, differentiation, and/or migration. The present invention is also based, at least in part, on the 15 discovery that the HGT-1 molecules of the present invention are differentially expressed (*e.g.*, upregulated) in different types of tumor cells, *e.g.*, breast, lung, and colon tumor cells. The present invention is still further based, at least in part, on the discovery that the HGT-1 molecules of the present invention are upregulated during the progression from attachment-dependent to attachment-independent growth of pre-malignant and malignant cells (*e.g.*, 20 breast cells).

Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding HGT-1 polypeptides or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of HGT-1-encoding nucleic acids.

In one embodiment, the invention features an isolated nucleic acid molecule that includes the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3. In another embodiment, the invention features an isolated nucleic acid molecule that encodes a polypeptide including the amino acid sequence set forth in SEQ ID NO:2. In another embodiment, the invention features an isolated nucleic acid molecule that includes the 30 nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number

In still other embodiments, the invention features isolated nucleic acid molecules including nucleotide sequences that are substantially identical (*e.g.*, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 35 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical) to the nucleotide sequence set forth as SEQ ID NO:1 or SEQ ID NO:3. The invention further features isolated nucleic acid molecules including at least 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 615, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300,

1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000,
2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700,
2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400,
3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, or 4000 contiguous
5 nucleotides of the nucleotide sequence set forth as SEQ ID NO:1 or SEQ ID NO:3. In
another embodiment, the invention features isolated nucleic acid molecules which encode a
polypeptide including an amino acid sequence that is substantially identical (*e.g.*, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%,
99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical) to the amino acid
10 sequence set forth as SEQ ID NO:2. The present invention also features nucleic acid
molecules which encode allelic variants of the polypeptide having the amino acid sequence
set forth as SEQ ID NO:2. In addition to isolated nucleic acid molecules encoding full-
length polypeptides, the present invention also features nucleic acid molecules which
encode fragments, for example, biologically active or antigenic fragments, of the full-length
15 polypeptides of the present invention (*e.g.*, fragments including at least 10, 15, 20, 25, 30,
35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, or 375 contiguous
amino acid residues of the amino acid sequence of SEQ ID NO:2). In still other
embodiments, the invention features nucleic acid molecules that are complementary to,
antisense to, or hybridize under stringent conditions to the isolated nucleic acid molecules
20 described herein.

In another aspect, the invention provides vectors including the isolated nucleic acid
molecules described herein (*e.g.*, HGT-1-encoding nucleic acid molecules). Such vectors
can optionally include nucleotide sequences encoding heterologous polypeptides. Also
featured are host cells including such vectors (*e.g.*, host cells including vectors suitable for
25 producing HGT-1 nucleic acid molecules and polypeptides).

In another aspect, the invention features isolated HGT-1 polypeptides and/or
biologically active or antigenic fragments thereof. Exemplary embodiments feature a
polypeptide including the amino acid sequence set forth as SEQ ID NO:2, a polypeptide
including an amino acid sequence at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%,
30 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9% identical to the amino acid sequence set forth as SEQ ID NO:2, a
polypeptide encoded by a nucleic acid molecule including a nucleotide sequence at least
60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,
99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to the
35 nucleotide sequence set forth as SEQ ID NO:1 or SEQ ID NO:3. Also featured are
fragments of the full-length polypeptides described herein (*e.g.*, fragments including at least
10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350,
or 375 contiguous amino acid residues of the sequence set forth as SEQ ID NO:2) as well as

allelic variants of the polypeptide having the amino acid sequence set forth as SEQ ID NO:2.

The HGT-1 polypeptides and/or biologically active or antigenic fragments thereof, are useful, for example, as reagents or targets in assays applicable to treatment and/or diagnosis of galactosyltransferase associated disorders and/or cellular proliferation, growth, differentiation, and/or migration disorders. In one embodiment, an HGT-1 polypeptide or fragment thereof, has an HGT-1 activity. In another embodiment, an HGT-1 polypeptide or fragment thereof, has a transmembrane domain and/or a galactosyltransferase family domain, and optionally, has an HGT-1 activity. In a related aspect, the invention features antibodies (*e.g.*, antibodies which specifically bind to any one of the polypeptides described herein) as well as fusion polypeptides including all or a fragment of a polypeptide described herein.

The present invention further features methods for detecting HGT-1 polypeptides and/or HGT-1 nucleic acid molecules, such methods featuring, for example, a probe, primer or antibody described herein. Also featured are kits *e.g.*, kits for the detection of HGT-1 polypeptides and/or HGT-1 nucleic acid molecules. In a related aspect, the invention features methods for identifying compounds which bind to and/or modulate the activity of an HGT-1 polypeptide or HGT-1 nucleic acid molecule described herein. Further featured are methods for modulating an HGT-1 activity.

In other embodiments, the invention provides methods for identifying a subject having a cellular proliferation, growth, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, differentiation, and/or migration disorder; methods for identifying a compound capable of treating a cellular proliferation, growth, differentiation, and/or migration disorder characterized by aberrant HGT-1 nucleic acid expression or HGT-1 polypeptide activity; and methods for treating a subject having a cellular proliferation, growth, differentiation, and/or migration disorder characterized by aberrant HGT-1 polypeptide activity or aberrant HGT-1 nucleic acid expression

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figures 1A-1C depict the cDNA sequence and predicted amino acid sequence of human HGT-1. The nucleotide sequence corresponds to nucleic acids 1 to 4052 of SEQ ID NO:1. The amino acid sequence corresponds to amino acids 1 to 378 of SEQ ID NO:2. The coding region without the 5' and 3' untranslated regions of the human HGT-1 gene is shown in SEQ ID NO:3.

Figure 2 depicts a structural, hydrophobicity, and antigenicity analysis of the human HGT-1 polypeptide.

Figure 3 depicts the results of a search which was performed against the HMM database in PFAM and which resulted in the identification of one “galactosyltransferase family domain” in the human HGT-1 polypeptide (SEQ ID NO:2).

Figure 4 depicts the results of a search which was performed against the MEMSAT database and which resulted in the identification of one “transmembrane domain” in the human HGT-1 polypeptide (SEQ ID NO:2).

Figure 5 depicts the expression levels of human HGT-1 in various human tumors and normal human tissues, as determined by Taqman analysis. Sample No.: (1) normal artery; (2) aortic smooth muscle cells - early; (3) coronary smooth muscle cells; (4) human umbilical vein endothelial cells (HUVECs) - static; (5) human umbilical vein endothelial cells (HUVECs) - shear; (6) normal heart; (7) heart - congestive heart failure (CHF); (8) kidney; (9) skeletal muscle; (10) normal adipose tissue; (11) pancreas; (12) primary osteoblasts; (13) osteoclasts (differentiated); (14) normal skin; (15) normal spinal cord; (16) normal brain cortex; (17) brain - hypothalamus; (18) nerve; (19) dorsal root ganglion (DRG); (20) glial cells (astrocytes); (21) glioblastoma; (22) normal breast; (23) breast tumor; (24) normal ovary; (25) ovary tumor; (26) normal prostate; (27) prostate tumor; (28) prostate epithelial cells; (29) normal colon; (30) colon tumor; (31) normal lung; (32) lung tumor; (33) lung - chronic obstructive pulmonary disease (COPD); (34) colon - inflammatory bowel disease (IBD); (35) normal liver; (36) liver - fibrosis; (37) dermal cells - fibroblasts; (38) normal spleen; (39) normal tonsil; (40) lymph node; (41) resting peripheral blood mononuclear cells (PBMC); (42) skin - decubitus; (43) synovium; (44) bone marrow mononuclear cells (BM-MNC); (45) activated PBMC.

Figure 6 depicts the expression levels of human HGT-1 in various human tumors, as determined by Taqman analysis. Sample No.: (1-3) normal breast; (4) breast tumor - infiltrating ductal carcinoma (IDC); (5) breast tumor - moderately differentiated IDC (MD-IDC); (6) breast tumor - poorly differentiated IDC (IDC-PD); (7) breast tumor - infiltrating ductal carcinoma / invasive lobular carcinoma (IDC/ILC); (8) breast tumor - IDC; (9) breast tumor; (10-11) normal ovary; (12-16) ovary tumor; (17-19) normal lung; (20) lung tumor - small cell carcinoma (SmC); (21-22) lung tumor - poorly differentiated non-small cell carcinoma of the lung (PDNSCCL); (23-24) lung tumor - squamous cell carcinoma (SCC); (25) lung tumor - adenocarcinoma (AC); (26) lung tumor - PDNSCCL; (27) normal human bronchial epithelium (NBHE); (28-30) normal colon; (31-32) colon tumor - moderately differentiated (MD); (33) colon tumor; (34) colon tumor - moderately differentiated / poorly differentiated (MD-PD); (35-36) colon tumor - liver metastasis; (37) normal liver (female); (38) hemangioma; (39) human microvascular endothelial cells (HMVECs) - arrested; (40) HMVECs - proliferating.

Figure 7 depicts the expression levels of human HGT-1 in various human lung cancer models, as determined by Taqman analysis. Sample No.: (1) normal human bronchial epithelium (NHBE); (2) A549 (BA); (3) H460 - large cell lung carcinoma (LCLC); (4) H23 - adenocarcinoma (AC); (5) H522 - AC; (6) H125 adenocarcinoma / squamous cell carcinoma (AC/SCC); (7) H520 - squamous cell carcinoma (SCC); (8) H69 - small cell lung cancer (SCLC); (9) H345 - SCLC; (10) H460 - INCX 24 hours; (11) H460 - p16 - 24 hours; (12) H460 - INCX - 48 hours; (13) H460 p16 - 48 hours; (14) H460 - INCX - stable - plastic; (15) H460 - p16 stable - plastic; (16) H460 NA-Agar; (17) H460 - INCX - stable - Agar; (18) H460 - p16 stable - Agar; (19) H125 - INCX - 96 hours; (20) H125 - p53 - 96 hours; (21) H345 - Mock - 144 hours; (22) H345 - Gluc - 144 hours; (23) H345 - VIP - 144 hours.

Figure 8 depicts the expression levels of human HGT-1 in various human breast cancer models, as determined by Taqman analysis. Sample No.: (1) MCF10MS (mortal cells, grown in serum-containing medium); (2) MCF10A (immortalized but otherwise normal, grown as attached cells); (3) MCF10AT.cl1 (pre-malignant, with potential for neoplastic progression); (4) MCF10AT.cl3; (5) MCF10AT 1; (6) MCF10AT 3B; (7) MCF10CA 1a.cl1 (fully malignant); (8) MCF10AT 3B Agar; (9) MCF10CA 1a.cl1 - Agar; (10) MCF10A m25 - plastic; (11) MCF10CA - Agar; (12) MCF10CA - plastic; (13) MCF3B (breast cancer, stably expressing the Na⁺/I symporter (NIS)) - Agar; (14) MCF3B - plastic; (15) MCF10A - EGF 0 hours; (16) MCF10A - EGF 0.5 hours; (17) MCF10A - EGF 1 hour; (18) MCF10A - EGF 2 hours; (19) MCF10A - EGF 4 hours; (20) MCF10A - EGF 8 hours; (21) MCF10A - IGF1A 0 hours; (22) MCF10A - IGF1A 0.5 hours; (23) MCF10A - IGF1A 1 hour; (24) MCF10A - IGF1A 3 hours; (25) MCF10A - IGF1A 25 hours; (26) MCF10AT 3B.cl5 - plastic; (27) MCF10AT 3B.cl6 - plastic; (28) MCF10AT 3B.cl3 - plastic; (29) MCF10AT 3B.cl1 plastic; (30) MCF10AT 3B.cl4 - plastic; (31) MCF10AT 3B.cl2 - plastic; (32) MCF10AT 3B.cl5 - Agar; (33) MCF10AT 3B.cl6 - Agar; (34) MCF-7; (35) ZR-75; (36) T47D; (37) MDA-231; (38) MDA-435; (39) SkBr3; (40) Ha578Bst; (41) Ha578T.

Detailed Description of the Invention

The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as “human galactosyltransferase-1” or “HGT-1” nucleic acid and polypeptide molecules, which are novel members of the galactosyltransferase family. These novel molecules are capable of forming a glycosidic bond between molecules, *e.g.*, between UDP-galactose and N-acetylglicosamine and, thus, play a role in or function in a variety of cellular processes, *e.g.*, maintenance of cell physiology and lactose homeostasis, and/or cellular proliferation, growth, differentiation, and/or migration. The present invention is also based, at least in part, on the discovery that the HGT-1 molecules of the present invention are differentially expressed (*e.g.*, upregulated) in different types of tumor cells,

e.g., breast, lung, and colon tumor cells. the present invention is still further based, at least in part, on the discovery that the HGT-1 molecules of the present invention are upregulated during the progression from attachment-dependent to attachment-independent growth of pre-malignant and malignant cells (e.g., breast cells).

5 As used herein, a “galactosyltransferase” includes a protein or polypeptide which is involved in forming a glycosidic bond between molecules, e.g., between UDP-galactose and N-acetylglucosamine (e.g., N-acetylglucosamine on a polysaccharide or glycoprotein), in a cell (e.g., in the Golgi complex (e.g., the *trans* Golgi)). Galactosyltransferase family members regulate lactose homeostasis in a cell (i.e., via the formation of a glycosidic bond
10 between galactose and glucose molecules) and, typically, have UDP-galactose specificity. Galactosyltransferase family members share a common topology: they are integral membrane proteins that possess a short amino-terminal cytoplasmic domain, a transmembrane domain, a stem region of variable length, and a carboxy-terminal catalytic domain. Although most members of this family are membrane bound, they may be
15 proteolytically cleaved into soluble forms which may be secreted.

As used herein, a “galactosyltransferase mediated activity” includes an activity which involves a galactosyltransferase in a cell (e.g., in the Golgi complex (e.g., the *trans* Golgi)). Galactosyltransferase mediated activities include formation of a glycosidic bond between molecules, e.g., between UDP-galactose and N-acetylglucosamine (e.g., N-
20 acetylglucosamine on a polysaccharide or glycoprotein); regulation of lactose homeostasis; the participation in signal transduction pathways associated with oligosaccharide metabolism and glycoprotein glycosylation; and/or regulation of cellular differentiation, growth, differentiation, and/or migration.

As the HGT-1 molecules of the present invention are galactosyltransferases, they
25 may be useful for developing novel diagnostic and therapeutic agents for galactosyltransferase associated disorders. As used herein, the term “galactosyltransferase associated disorder” includes a disorder, disease, or condition which is characterized by an aberrant, e.g., upregulated or downregulated, galactosyltransferase mediated activity. Galactosyltransferase associated disorders typically result in upregulated or downregulated,
30 oligosaccharide levels in a cell. Examples of galactosyltransferase associated disorders include disorders associated with oligosaccharide homeostasis, such as rheumatoid arthritis, juvenile chronic arthritis, Sjorgren’s syndrome, permanent mixed-field polyagglutinability, leukemia, lymphoma, colon cancer, and breast cancer.

As demonstrated herein, the HGT-1 molecules of the present invention are
35 differentially expressed (e.g., upregulated) in different types of tumor cells. Accordingly, the HGT-1 molecules of the present invention may be useful for developing novel diagnostic and therapeutic agents for cellular proliferation, growth, differentiation, and/or migration disorders. As used herein, “cellular proliferation, growth, differentiation, and/or

migration disorders” include those disorders that affect cellular proliferation, growth, differentiation, and/or migration processes. As used herein, a “cellular proliferation, growth, differentiation, and/or migration process” is a process by which a cell increases in number, size or content, by which a cell develops a specialized set of characteristics which

5 differ from that of other cells, or by which a cell moves closer to or further from a particular location or stimulus. Examples of cellular proliferation, growth, differentiation, and/or migration disorders include cancer, *e.g.*, ovarian cancer, breast cancer, colon cancer, lung cancer, brain cancer, as well as other types of carcinomas, sarcomas, lymphomas, and/or leukemias; tumor angiogenesis and metastasis; skeletal dysplasia; hepatic disorders; and

10 hematopoietic and/or myeloproliferative disorders.

As further demonstrated herein, the HGT-1 molecules of the present invention are differentially expressed (*e.g.*, upregulated or downregulated) in human umbilical vein endothelial cells (HUVECs) under conditions of shear stress, and in the heart of subjects and animal models suffering from congestive heart failure. As used herein, the term

15 “cardiovascular disorder” includes a disorder, disease or condition which affects the cardiovascular system, *e.g.*, the heart or blood vessels. Cardiovascular disorders can detrimentally affect cellular functions such as calcium transport and inter- or intra-cellular communication; and tissue functions such as angiogenesis, vascular smooth muscle tone, vascular function, and cardiac function. Examples of cardiovascular disorders include

20 cardiovascular disorders include hypertension, arteriosclerosis, ischemia reperfusion injury, restenosis, arterial inflammation, vascular wall remodeling, ventricular remodeling, rapid ventricular pacing, coronary microembolism, tachycardia, bradycardia, pressure overload, aortic bending, coronary artery ligation, vascular heart disease, atrial fibrillation, Jervell syndrome, Lange-Nielsen syndrome, long-QT syndrome, congestive heart failure, sinus

25 node dysfunction, angina, heart failure, atrial fibrillation, atrial flutter, dilated cardiomyopathy, idiopathic cardiomyopathy, myocardial infarction, coronary artery disease, coronary artery spasm, arrhythmia, atherosclerosis, transplant atherosclerosis, varicose veins, migraine headaches, cluster headaches, vascular disease, diabetic vascular disease, pulmonary vascular disease, peripheral vascular disease, renovascular hypertension,

30 intravascular tumor, pulmonary vasculitis, vascular tone disorders in pregnancy, pulmonary capillaritis, peripheral arterial disease, idiopathic hypereosinophilic syndrome, aortic aneurysm, respiratory disease, vasospasm, systemic sclerosis, preeclampsia, graft vessel disease, cardiac allograft vasculopathy, vascular ischemic injury, familial amyloidotic polyneuropathy, acute atherosclerosis, cardiovascular disease, Kawasaki disease, ischemic

35 syndromes, chronic heart failure, and fibrosis.

The term “family” when referring to the polypeptide and nucleic acid molecules of the invention is intended to mean two or more polypeptides or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide

sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first polypeptide of human origin, as well as other, distinct polypeptides of human origin or alternatively, can contain homologues of non-human origin, e.g., mouse or monkey polypeptides. Members of a family may also have common functional characteristics.

For example, the family of HGT-1 polypeptides comprise at least one “transmembrane domain.” As used herein, the term “transmembrane domain” includes an amino acid sequence of about 15-45 amino acid residues in length which spans the plasma membrane. More preferably, a transmembrane domain includes about at least 15, 20, 25, 30, 35, 40, or 45 amino acid residues and spans the plasma membrane. Transmembrane domains are rich in hydrophobic residues, and typically have an alpha-helical structure. In a preferred embodiment, at least 50%, 60%, 70%, 80%, 90%, 95% or more of the amino acids of a transmembrane domain are hydrophobic, e.g., leucines, isoleucines, alanines, valines, phenylalanines, prolines or methionines. Transmembrane domains are described in, for example, Zagotta W.N. *et al.* (1996) *Annu. Rev. Neurosci.* 19:235-263, the contents of which are incorporated herein by reference. A MEMSAT analysis resulted in the identification of one transmembrane domain in the amino acid sequence of human HGT-1 (SEQ ID NO:2) at about residues 15-32 as set forth in Figure 4.

Accordingly, HST -1 polypeptides having at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with a transmembrane domain of human HST -1 are within the scope of the invention.

In another embodiment, an HGT-1 molecule of the present invention is identified based on the presence of at least one “galactosyltransferase family domain.” As used herein, the term “galactosyltransferase family domain” includes a protein domain having at least about 100-300 amino acid residues, having a bit score of at least 100 when compared against a galactosyltransferase family domain Hidden Markov Model (HMM), and a galactosyltransferase mediated activity. Preferably, a galactosyltransferase family domain includes a polypeptide having an amino acid sequence of about 125-275, 150-250, 175-225, or more preferably, about 219 amino acid residues, a bit score of at least 140, 150, 160, or more preferably about 173.8, and a galactosyltransferase mediated activity. To identify the presence of a galactosyltransferase family domain in an HGT-1 protein, and make the determination that a protein of interest has a particular profile, the amino acid sequence of the protein may be searched against a database of known protein domains (e.g., the PFAM HMM database). A PFAM galactosyltransferase family domain has been assigned the PFAM Accession PF01762. A search was performed against the PFAM HMM database resulting in the identification of a galactosyltransferase family domain in the amino acid

sequence of human HGT-1 (SEQ ID NO:2) at about residues 102-321 of SEQ ID NO:2. The results of the search are set forth in Figure 3.

A description of the Pfam database can be found in Sonhammer *et al.* (1997) *Proteins* 28:405-420 and a detailed description of HMMs can be found, for example, in 5 Gribskov *et al.* (1990) *Methods Enzymol.* 183:146-159; Gribskov *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:4355-4358; Krogh *et al.* (1994) *J. Mol. Biol.* 235:1501-1531; and Stultz *et al.* (1993) *Protein Sci.* 2:305-314, the contents of which are incorporated herein by reference.

Preferably a “galactosyltransferase family domain” has a “galactosyltransferase mediated activity” as described herein. For example, a galactosyltransferase family domain 10 may have the ability to form a glycosidic bond between molecules, *e.g.*, between UDP-galactose and N-acetylglucosamine (*e.g.*, N-acetylglucosamine on a polysaccharide or glycoprotein), in a cell (*e.g.*, in the Golgi complex (*e.g.*, the *trans* Golgi)); and the ability to regulate lactose homeostasis in a cell. Accordingly, identifying the presence of a 15 “galactosyltransferase family domain” can include isolating a fragment of an HGT-1 molecule (*e.g.*, an HGT-1 polypeptide) and assaying for the ability of the fragment to exhibit one of the aforementioned galactosyltransferase mediated activities.

In a preferred embodiment, the HGT-1 molecules of the invention include at least one transmembrane domain and/or at least one galactosyltransferase family domain.

Isolated polypeptides of the present invention, preferably HGT-1 polypeptides, have 20 an amino acid sequence sufficiently identical to the amino acid sequence of SEQ ID NO:2 or are encoded by a nucleotide sequence sufficiently identical to SEQ ID NO:1 or 3. As used herein, the term “sufficiently identical” refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (*e.g.*, an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a 25 second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 30 99.7%, 99.8%, 99.9% or more homology or identity across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently identical. Furthermore, amino acid or nucleotide sequences 35 which share at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more homology or identity and share a common functional activity are defined herein as sufficiently identical.

In a preferred embodiment, an HGT-1 polypeptide includes at least one or more of the following domains: a transmembrane domain and/or a galactosyltransferase family

domain, and has an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more homologous or identical to the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the DNA insert of 5 the plasmid deposited with ATCC as Accession Number _____. In yet another preferred embodiment, an HGT-1 polypeptide includes at least one or more of the following domains: a transmembrane domain and/or a galactosyltransferase family domain, and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a complement of a nucleic acid molecule comprising the 10 nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. In another preferred embodiment, an HGT-1 polypeptide includes at least one or more of the following domains: a transmembrane domain and/or a galactosyltransferase family domain, and has an HGT-1 activity.

As used interchangeably herein, an “HGT-1 activity”, “biological activity of HGT-1” or “functional activity of HGT-1”, includes an activity exerted by an HGT-1 polypeptide or nucleic acid molecule, for example, in an HGT-1 expressing cell or tissue, or on an HGT-1 target or substrate (*e.g.*, UDP-galactose and N-acetylglucosamine (*e.g.*, N-acetylglucosamine bound to a polysaccharide and/or a glycoprotein)), as determined *in vivo* or *in vitro*, according to standard techniques. In one embodiment, an HGT-1 activity is a direct activity, such as association with or enzymatic modification of an HGT-1-target molecule. As used herein, a “target molecule” or “binding partner” is a molecule with which an HGT-1 polypeptide binds or interacts in nature, such that HGT-1-mediated function is achieved. An HGT-1 target molecule can be a non- HGT-1 molecule or an HGT-1 polypeptide of the present invention. In an exemplary embodiment, an HGT-1 target molecule is an HGT-1 substrate (*e.g.*, an UDP-galactose and N-acetylglucosamine). Furthermore, an HGT-1 activity can be an indirect activity, such as a cellular signaling activity mediated by interaction of the HGT-1 polypeptide with an HGT-1 substrate or binding partner. The biological activities of HGT-1 are described herein.

For example, an HGT-1 molecule can have one or more of the following activities:

30 (i) it may bind UDP-galactose and N-acetylglucosamine (*e.g.*, N-acetylglucosamine bound to a glycoprotein); (ii) it may catalyze the formation of glycosidic bonds (*e.g.*, between UDP-galactose and N-acetylglucosamine); (iii) it may modulate lactose homeostasis; (iv) it may regulate embryogenesis; (v) it may regulate development; (vi) it may regulate the formation of structural elements of the cell; (vii) it may regulate the metabolism of adhesive 35 ligands; (viii) it may regulate the metabolism of glycoprotein ligands and receptors; (ix) it may regulate blood clotting; (x) it may regulate thrombus dissolution; (xi) it may regulate hormone action; (xii) it may regulate fertilization; (xiii) it may regulate an immune system

response; and (xiv) it may regulate cellular proliferation, growth, differentiation, and/or migration.

The nucleotide sequence of the isolated human HGT-1 cDNA and the predicted amino acid sequence of the human HGT-1 polypeptide are shown in Figures 1A-1C and in SEQ ID NOS:1 and 2, respectively. A plasmid containing the nucleotide sequence encoding human HGT-1 was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on _____ and assigned Accession Number _____. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

The human HGT-1 gene, which is approximately 4052 nucleotides in length, encodes a polypeptide having a molecular weight of approximately 41.6 kD and which is approximately 378 amino acid residues in length.

Various aspects of the invention are described in further detail in the following subsections:

I. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode HGT-1 polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify HGT-1-encoding nucleic acid molecules (*e.g.*, HGT-1 mRNA) and fragments for use as PCR primers for the amplification or mutation of HGT-1 nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

The term “isolated nucleic acid molecule” includes nucleic acid molecules which are separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term “isolated” includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5’ and 3’ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated HGT-1 nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the

nucleic acid is derived. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

5 A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID
10 NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, as a hybridization probe, HGT-1 nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, J. *et al.*, *Molecular Cloning: A Laboratory Manual*. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY,
15 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____ can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO:1 or 3,
20 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____.

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
25 Furthermore, oligonucleotides corresponding to HGT-1 nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In one embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1. The sequence of SEQ ID NO:1 corresponds to the human HGT-1 cDNA. This cDNA comprises sequences encoding the human HGT-1 polypeptide (*i.e.*, “the coding region”, from nucleotides 459-1592) as well as 5’ untranslated sequences (nucleotides 1-458) and 3’ untranslated sequences (nucleotides 1593-4052).

Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:1 (*e.g.*, nucleotides 459-1592, corresponding to SEQ ID NO:3). Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention comprises SEQ ID NO:3 and nucleotides 1-458 of SEQ ID NO:1. In yet another embodiment, the isolated nucleic acid molecule comprises SEQ ID NO:3 and nucleotides 1593-4052 of SEQ ID NO:1. In yet another embodiment, the nucleic acid molecule consists of the nucleotide

sequence set forth as SEQ ID NO:1 or SEQ ID NO:3. In still another embodiment, the nucleic acid molecule can comprise the coding region of SEQ ID NO:1 (e.g., nucleotides 459-1592, corresponding to SEQ ID NO:3), as well as a stop codon (e.g., nucleotides 1593-1595 of SEQ ID NO:1). In other embodiments, the nucleic acid molecule can comprise 5 nucleotides 1-227, 658-748, 1142-1494, or 2149-2489 of SEQ ID NO:1.

In still another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a portion of any of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 10 _____, such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 15 _____, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 50%, 55%, 60%, 20 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more identical to the nucleotide sequence shown in SEQ ID NO:1 or 3 (e.g., to the entire length of the nucleotide sequence), or to the nucleotide sequence (e.g., the entire length of the nucleotide sequence) 25 of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a portion of any of these nucleotide sequences. In one embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least (or no greater than) 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 615, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 30 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000 or more nucleotides in length and 35 hybridizes under stringent hybridization conditions to a complement of a nucleic acid molecule of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, for example, a

fragment which can be used as a probe or primer or a fragment encoding a portion of an HGT-1 polypeptide, *e.g.*, a biologically active portion of an HGT-1 polypeptide. The nucleotide sequence determined from the cloning of the HGT-1 gene allows for the generation of probes and primers designed for use in identifying and/or cloning other HGT-
5 1 family members, as well as HGT-1 homologues from other species. The probe/primer typically comprises substantially purified oligonucleotide. The probe/primer (*e.g.*, oligonucleotide) typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, 75, 80, 85, 90, 95, or 100 or more consecutive
10 nucleotides of a sense sequence of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, of an anti-sense sequence of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or of a naturally occurring
15 allelic variant or mutant of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____.

Exemplary probes or primers are at least 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or more nucleotides in length and/or comprise consecutive nucleotides of an isolated nucleic acid molecule described herein. Probes based on the HGT-1 nucleotide sequences can be used to detect (*e.g.*, specifically detect) transcripts or genomic sequences
20 encoding the same or homologous polypeptides. In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. In another embodiment a set of primers is provided, *e.g.*, primers suitable for use in a PCR, which can be used to amplify
25 a selected region of an HGT-1 sequence, *e.g.*, a domain, region, site or other sequence described herein. The primers should be at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more nucleotides in length. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress an HGT-1 polypeptide, such as by measuring a level of an HGT-1-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting
30 HGT-1 mRNA levels or determining whether a genomic HGT-1 gene has been mutated or deleted.

A nucleic acid fragment encoding a “biologically active portion of an HGT-1 polypeptide” can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, which encodes a polypeptide having an HGT-1
35 biological activity (the biological activities of the HGT-1 polypeptides are described herein), expressing the encoded portion of the HGT-1 polypeptide (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the HGT-1 polypeptide. In an exemplary embodiment, the nucleic acid molecule is at least 50, 75, 100, 150, 200, 250,

300, 350, 400, 450, 500, 550, 600, 615, 650, 700, 750, 800, 850, 900, 950, 1000, 1050,
1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750,
1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450,
2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150,
5 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850,
3900, 3950, 4000 or more nucleotides in length and encodes a polypeptide having an HGT-1
activity (as described herein).

The invention further encompasses nucleic acid molecules that differ from the
nucleotide sequence shown in SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA
10 insert of the plasmid deposited with ATCC as Accession Number _____. Such differences
can be due to degeneracy of the genetic code, thus resulting in a nucleic acid which
encodes the same HGT-1 polypeptides as those encoded by the nucleotide sequence shown
in SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid
deposited with ATCC as Accession Number _____. In another embodiment, an isolated
15 nucleic acid molecule of the invention has a nucleotide sequence encoding a polypeptide
having an amino acid sequence which differs by at least 1, but no greater than 5, 10, 20, 50
or 100 amino acid residues from the amino acid sequence shown in SEQ ID NO:2, or the
amino acid sequence encoded by the DNA insert of the plasmid deposited with the ATCC as
Accession Number _____. In yet another embodiment, the nucleic acid molecule encodes
20 the amino acid sequence of human HGT-1. If an alignment is needed for this comparison,
the sequences should be aligned for maximum homology.

Nucleic acid variants can be naturally occurring, such as allelic variants (same locus),
homologues (different locus), and orthologues (different organism) or can be non naturally
occurring. Non-naturally occurring variants can be made by mutagenesis techniques, including
25 those applied to polynucleotides, cells, or organisms. The variants can contain nucleotide
substitutions, deletions, inversions and insertions. Variation can occur in either or both the
coding and non-coding regions. The variations can produce both conservative and non-
conservative amino acid substitutions (as compared in the encoded product).

Allelic variants result, for example, from DNA sequence polymorphisms within a
30 population (e.g., the human population) that lead to changes in the amino acid sequences of
the HGT-1 polypeptides. Such genetic polymorphism in the HGT-1 genes may exist among
individuals within a population due to natural allelic variation. As used herein, the terms
“gene” and “recombinant gene” refer to nucleic acid molecules which include an open
reading frame encoding an HGT-1 polypeptide, preferably a mammalian HGT-1
35 polypeptide, and can further include non-coding regulatory sequences, and introns.

Accordingly, in one embodiment, the invention features isolated nucleic acid
molecules which encode a naturally occurring allelic variant of a polypeptide comprising the
amino acid sequence of SEQ ID NO:2, or an amino acid sequence encoded by the DNA

insert of the plasmid deposited with ATCC as Accession Number _____, wherein the nucleic acid molecule hybridizes to a complement of a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3, for example, under stringent hybridization conditions.

Allelic variants of human HGT-1 include both functional and non-functional HGT-1 polypeptides. Functional allelic variants are naturally occurring amino acid sequence variants of the human HGT-1 polypeptide that have an HGT-1 activity, e.g., maintain the ability to bind an HGT-1 ligand or substrate and/or modulate galactosyltransferase activity, and/or modulate lactose homeostasis. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID NO:2, or substitution, deletion or insertion of non-critical residues in non-critical regions of the polypeptide.

Non-functional allelic variants are naturally occurring amino acid sequence variants of the human HGT-1 polypeptide that do not have an HGT-1 activity, e.g., they do not have the ability to bind UDP-galactose and N-acetylglucosamine, form glycosidic bonds or to modulate lactose homeostasis. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion or premature truncation of the amino acid sequence of SEQ ID NO:2, or a substitution, insertion or deletion in critical residues or critical regions.

The present invention further provides non-human orthologues of the human HGT-1 polypeptide. Orthologues of human HGT-1 polypeptides are polypeptides that are isolated from non-human organisms and possess the same HGT-1 activity, e.g., ligand binding, and/or modulation of galactosyltransferase activities, and/or modulation of lactose homeostasis, as the human HGT-1 polypeptide. Orthologues of the human HGT-1 polypeptide can readily be identified as comprising an amino acid sequence that is substantially identical to SEQ ID NO:2.

Moreover, nucleic acid molecules encoding other HGT-1 family members and, thus, which have a nucleotide sequence which differs from the HGT-1 sequences of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____ are intended to be within the scope of the invention. For example, another HGT-1 cDNA can be identified based on the nucleotide sequence of human HGT-1. Moreover, nucleic acid molecules encoding HGT-1 polypeptides from different species, and which, thus, have a nucleotide sequence which differs from the HGT-1 sequences of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____ are intended to be within the scope of the invention. For example, a mouse HGT-1 cDNA can be identified based on the nucleotide sequence of a human HGT-1.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the HGT-1 cDNAs of the invention can be isolated based on their homology to the HGT-1 nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a

hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Nucleic acid molecules corresponding to natural allelic variants and homologues of the HGT-1 cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the HGT-1 gene.

5 Orthologues, homologues and allelic variants can be identified using methods known in the art (e.g., by hybridization to an isolated nucleic acid molecule of the present invention, for example, under stringent hybridization conditions). In one embodiment, an isolated nucleic acid molecule of the invention is at least 15, 20, 25, 30 or more nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising 10 the nucleotide sequence of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In other embodiment, the nucleic acid is at least 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 15 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000 or more nucleotides in length.

20 As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences that are significantly identical or homologous to each other remain hybridized to each other. Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about 85% or 90% identical to each other remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, Ausubel *et al.*, eds., John Wiley & Sons, Inc. (1995), sections 2, 4 and 6. Additional stringent conditions can be found 25 in *Molecular Cloning: A Laboratory Manual*, Sambrook *et al.*, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), chapters 7, 9 and 11. A preferred, non-limiting example of stringent hybridization conditions includes hybridization in 4X sodium chloride/sodium citrate (SSC), at about 65-70°C (or hybridization in 4X SSC plus 50% formamide at about 30 42-50°C) followed by one or more washes in 1X SSC, at about 65-70°C. A preferred, non-limiting example of highly stringent hybridization conditions includes hybridization in 1X SSC, at about 65-70°C (or hybridization in 1X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 0.3X SSC, at about 65-70°C. A preferred, non-limiting 35 example of reduced stringency hybridization conditions includes hybridization in 4X SSC, at about 50-60°C (or alternatively hybridization in 6X SSC plus 50% formamide at about 40-45°C) followed by one or more washes in 2X SSC, at about 50-60°C. Ranges intermediate to the above-recited values, e.g., at 65-70°C or at 42-50°C are also intended to be encompassed by the present invention. SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄,

and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes each after hybridization is complete. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature
5 (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, $T_m(^{\circ}\text{C}) = 2(\# \text{ of A + T bases}) + 4(\# \text{ of G + C bases})$. For hybrids between 18 and 49 base pairs in length, $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{G+C}) - (600/N)$, where N is the number of bases in the hybrid, and $[\text{Na}^+]$ is the concentration of sodium ions in the hybridization buffer ($[\text{Na}^+]$ for 1xSSC = 10 0.165 M). It will also be recognized by the skilled practitioner that additional reagents may be added to hybridization and/or wash buffers to decrease non-specific hybridization of nucleic acid molecules to membranes, for example, nitrocellulose or nylon membranes, including but not limited to blocking agents (e.g., BSA or salmon or herring sperm carrier DNA), detergents (e.g., SDS), chelating agents (e.g., EDTA), Ficoll, PVP and the like.
15 When using nylon membranes, in particular, an additional preferred, non-limiting example of stringent hybridization conditions is hybridization in 0.25-0.5M NaH₂PO₄, 7% SDS at about 65°C, followed by one or more washes at 0.02M NaH₂PO₄, 1% SDS at 65°C, see e.g., Church and Gilbert (1984) *Proc. Natl. Acad. Sci. USA* 81:1991-1995 (or alternatively 0.2X SSC, 1% SDS).

20 Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1 or 3 and corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural polypeptide).

25 In addition to naturally-occurring allelic variants of the HGT-1 sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, thereby leading to changes in the amino acid sequence of the encoded HGT-1 polypeptides, without altering the functional ability of the HGT-1 polypeptides. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of HGT-1 (e.g., the sequence of SEQ ID NO:2) without altering the biological activity, whereas an “essential” amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the HGT-1 polypeptides of the present invention, e.g., those present in a transmembrane domain and/or a

galactosyltransferase family domain, are predicted to be particularly unamenable to alteration. Furthermore, additional amino acid residues that are conserved between the HGT-1 polypeptides of the present invention and other members of the HGT-1 family are not likely to be amenable to alteration.

5 Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding HGT-1 polypeptides that contain changes in amino acid residues that are not essential for activity. Such HGT-1 polypeptides differ in amino acid sequence from SEQ ID NO:2, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises 10 an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more identical to SEQ ID NO:2 (*e.g.*, to the entire length of SEQ ID NO:2).

15 An isolated nucleic acid molecule encoding an HGT-1 polypeptide identical to the polypeptide of SEQ ID NO:2, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded polypeptide. Mutations can be introduced into SEQ ID NO:1 or 20 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____ by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at 25 one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, 30 phenylalanine, methionine), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an HGT-1 polypeptide is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an HGT-1 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for 35 HGT-1 biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited

with ATCC as Accession Number _____, the encoded polypeptide can be expressed recombinantly and the activity of the polypeptide can be determined.

In a preferred embodiment, a mutant HGT-1 polypeptide can be assayed for the ability to (i) bind UDP-galactose and N-acetylglucosamine (*e.g.*, N-acetylglucosamine bound to a glycoprotein); (ii) catalyze the formation of glycosidic bonds (*e.g.*, between UDP-galactose and N-acetylglucosamine); (iii) modulate lactose homeostasis; (iv) regulate embryogenesis; (v) regulate development; (vi) regulate the formation of structural elements of the cell; (vii) regulate the metabolism of adhesive ligands; (viii) regulate the metabolism of glycoprotein ligands and receptors; (ix) regulate blood clotting; (x) regulate thrombus dissolution; (xi) regulate hormone action; (xii) regulate fertilization; (xiii) regulate an immune system response; and/or (xiv) regulate cellular proliferation, growth, differentiation, and/or migration.

In addition to the nucleic acid molecules encoding HGT-1 polypeptides described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. In an exemplary embodiment, the invention provides an isolated nucleic acid molecule which is antisense to an HGT-1 nucleic acid molecule (*e.g.*, is antisense to the coding strand of an HGT-1 nucleic acid molecule). An “antisense” nucleic acid comprises a nucleotide sequence which is complementary to a “sense” nucleic acid encoding a polypeptide, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire HGT-1 coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding HGT-1. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the coding region of human HGT-1 corresponds to SEQ ID NO:3). In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding HGT-1. The term “noncoding region” refers to 5’ and 3’ sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5’ and 3’ untranslated regions).

Given the coding strand sequences encoding HGT-1 disclosed herein (*e.g.*, SEQ ID NO:3), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of HGT-1 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of HGT-1 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of HGT-1 mRNA (*e.g.*, between the -10 and +10 regions of the start site of a gene nucleotide sequence). An antisense oligonucleotide can be, for example, about

5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or
5 variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine,
10 xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense
15 nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
20

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an HGT-1 polypeptide to thereby inhibit expression of the polypeptide, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs
25
30
35

in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haseloff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave HGT-1 mRNA transcripts to thereby inhibit translation of HGT-1 mRNA. A ribozyme having specificity for an HGT-1-encoding nucleic acid can be designed based upon the nucleotide sequence of an HGT-1 cDNA disclosed herein (*i.e.*, SEQ ID NO:1 or 3, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number ____). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an HGT-1-encoding mRNA. See, *e.g.*, Cech *et al.*, U.S. Patent No. 4,987,071; and Cech *et al.*, U.S. Patent No. 5,116,742. Alternatively, HGT-1 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

Alternatively, HGT-1 gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the HGT-1 (*e.g.*, the HGT-1 promoter and/or enhancers) to form triple helical structures that prevent transcription of the HGT-1 gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioessays* 14(12):807-15.

In yet another embodiment, the HGT-1 nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup, B. and Nielsen, P.E. (1996) *Bioorg. Med. Chem.* 4(1):5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral

backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup and Nielsen (1996) *supra* and Perry-O'Keefe *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:14670-675.

5 PNAs of HGT-1 nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigenic agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of HGT-1 nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene (*e.g.*, by PNA-directed PCR clamping);
10 as 'artificial restriction enzymes' when used in combination with other enzymes (*e.g.*, S1 nucleases (Hyrup and Nielsen (1996) *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup and Nielsen (1996) *supra*; Perry-O'Keefe *et al.* (1996) *supra*).

In another embodiment, PNAs of HGT-1 can be modified (*e.g.*, to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of HGT-1 nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (*e.g.*, RNase H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup and Nielsen (1996) *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup and Nielsen (1996) *supra* and Finn, P. J. *et al.* (1996) *Nucleic Acids Res.* 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. *et al.* (1989) *Nucleic Acids Res.* 17:5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. *et al.* (1996) *supra*). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Petersen, K.H. *et al.* (1975) *Bioorganic Med. Chem. Lett.* 5:1119-1124).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered

cleavage agents (See, e.g., Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or intercalating agents (see, e.g., Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

5 Alternatively, the expression characteristics of an endogenous HGT-1 gene within a cell line or microorganism may be modified by inserting a heterologous DNA regulatory element into the genome of a stable cell line or cloned microorganism such that the inserted regulatory element is operatively linked with the endogenous HGT-1 gene. For example, an endogenous HGT-1 gene which is normally “transcriptionally silent”, i.e., an HGT-1 gene
10 which is normally not expressed, or is expressed only at very low levels in a cell line or microorganism, may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell line or microorganism. Alternatively, a transcriptionally silent, endogenous HGT-1 gene may be activated by insertion of a promiscuous regulatory element that works across cell types.
15

A heterologous regulatory element may be inserted into a stable cell line or cloned microorganism, such that it is operatively linked with an endogenous HGT-1 gene, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art, and described, e.g., in Chappel, U.S. Patent No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991.

II. Isolated HGT-1 Polypeptides and Anti-HGT-1 Antibodies

One aspect of the invention pertains to isolated HGT-1 or recombinant polypeptides and polypeptides, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-HGT-1 antibodies. In one embodiment, native HGT-1 polypeptides can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, HGT-1 polypeptides are produced by recombinant DNA techniques. Alternative to recombinant expression, an HGT-1 polypeptide or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An “isolated” or “purified” polypeptide or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the HGT-1 polypeptide is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of HGT-1 polypeptide in which the polypeptide is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language “substantially free of cellular material” includes preparations of HGT-1 polypeptide having less than about 30% (by dry weight) of non-HGT-1 polypeptide (also referred to herein as a “contaminating protein”),

more preferably less than about 20% of non-HGT-1 polypeptide, still more preferably less than about 10% of non-HGT-1 polypeptide, and most preferably less than about 5% non-HGT-1 polypeptide. When the HGT-1 polypeptide or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*,
5 culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of HGT-1 polypeptide in which the polypeptide is separated from chemical precursors or other chemicals which are involved in the synthesis of the polypeptide. In one
10 embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of HGT-1 polypeptide having less than about 30% (by dry weight) of chemical precursors or non-HGT-1 chemicals, more preferably less than about 20% chemical precursors or non-HGT-1 chemicals, still more preferably less than about 10% chemical precursors or non-HGT-1 chemicals, and most preferably less than about 5% chemical precursors or non-HGT-1 chemicals.
15

As used herein, a "biologically active portion" of an HGT-1 polypeptide includes a fragment of an HGT-1 polypeptide which participates in an interaction between an HGT-1 molecule and a non-HGT-1 molecule. Biologically active portions of an HGT-1 polypeptide include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the HGT-1 polypeptide, *e.g.*, the amino acid sequence shown in SEQ ID NO:2, which include less amino acids than the full length HGT-1 polypeptides, and exhibit at least one activity of an HGT-1 polypeptide. Typically, biologically active portions comprise a domain or motif with at least one activity of the HGT-1 polypeptide, *e.g.*, modulating galactosyltransferase activities. A biologically active portion of an HGT-1 polypeptide can be a polypeptide which is, for example, 25, 30, 35, 40,
20 45, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375 or more amino acids in length. Biologically active portions of an HGT-1 polypeptide can be used as targets for developing agents which modulate an HGT-1 activity.
25

In one embodiment, a biologically active portion of an HGT-1 polypeptide comprises at least one transmembrane domain. It is to be understood that a preferred biologically active portion of an HGT-1 polypeptide of the present invention comprises at least one or more of the following domains: a transmembrane domain and/or a galactosyltransferase family domain. Moreover, other biologically active portions, in which other regions of the polypeptide are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native HGT-1 polypeptide.
30
35

Another aspect of the invention features fragments of the polypeptide having the amino acid sequence of SEQ ID NO:2, for example, for use as immunogens. In one embodiment, a fragment comprises at least 5 amino acids (*e.g.*, contiguous or consecutive

amino acids) of the amino acid sequence of SEQ ID NO:2, or an amino acid sequence encoded by the DNA insert of the plasmid deposited with the ATCC as Accession Number _____. In another embodiment, a fragment comprises at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or more amino acids (e.g., contiguous or consecutive amino acids) of the amino acid sequence of SEQ ID NO:2, or an amino acid sequence encoded by the DNA insert of the plasmid deposited with the ATCC as Accession Number _____.
5

In a preferred embodiment, an HGT-1 polypeptide has an amino acid sequence shown in SEQ ID NO:2. In other embodiments, the HGT-1 polypeptide is substantially identical to SEQ ID NO:2, and retains the functional activity of the polypeptide of SEQ ID NO:2, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. In another embodiment, the HGT-1 polypeptide is a polypeptide which comprises an amino acid sequence at least about 50%, 55%, 60%, 65%, 10 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more identical to SEQ ID NO:2.
15

In another embodiment, the invention features an HGT-1 polypeptide which is encoded by a nucleic acid molecule consisting of a nucleotide sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more identical to a nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, or a complement thereof. This invention further features an HGT-1 polypeptide which is encoded by a nucleic acid molecule consisting of a nucleotide sequence which hybridizes under stringent hybridization conditions to a complement of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, or a complement thereof.
20
25

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence (e.g., when aligning a second sequence to the HGT-1 amino acid sequence of SEQ ID NO:2 having 378 amino acid residues, at least 113, 30 preferably at least 151, more preferably at least 189, more preferably at least 227, even more 35 preferably at least 265, and even more preferably at least 302 or 340 or more amino acid residues are aligned). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the

second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap,
5 which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been
10 incorporated into the GAP program in the GCG software package (available online through the Genetics Computer Group), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available online through
15 the Genetics Computer Group), using a NWGapDNA.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A preferred, non-limiting example of parameters to be used in conjunction with the GAP program include a Blosum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of Meyers, E. and Miller, W. (*Comput. Appl. Biosci.* 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0 or version 2.0U), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and polypeptide sequences of the present invention can further be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to HGT-1 nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 100, wordlength = 3, and a Blosum62 matrix to obtain amino acid sequences homologous to HGT-1 polypeptide molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and
30 Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See the internet website for the National Center for Biotechnology Information.
35

The invention also provides HGT-1 chimeric or fusion proteins. As used herein, an HGT-1 “chimeric protein” or “fusion protein” comprises an HGT-1 polypeptide operatively linked to a non-HGT-1 polypeptide. An “HGT-1 polypeptide” refers to a polypeptide having an amino acid sequence corresponding to HGT-1, whereas a “non-HGT-1 polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a polypeptide which is not substantially homologous to the HGT-1 polypeptide, *e.g.*, a polypeptide which is different from the HGT-1 polypeptide and which is derived from the same or a different organism. Within an HGT-1 fusion protein the HGT-1 polypeptide can correspond to all or a portion of an HGT-1 polypeptide. In a preferred embodiment, an HGT-1 fusion protein comprises at least one biologically active portion of an HGT-1 polypeptide. In another preferred embodiment, an HGT-1 fusion protein comprises at least two biologically active portions of an HGT-1 polypeptide. Within the fusion protein, the term “operatively linked” is intended to indicate that the HGT-1 polypeptide and the non-HGT-1 polypeptide are fused in-frame to each other. The non-HGT-1 polypeptide can be fused to the N-terminus or C-terminus of the HGT-1 polypeptide.

For example, in one embodiment, the fusion protein is a GST-HGT-1 fusion protein in which the HGT-1 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant HGT-1. In another embodiment, the fusion protein is an HGT-1 polypeptide containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of HGT-1 can be increased through the use of a heterologous signal sequence.

The HGT-1 fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. The HGT-1 fusion proteins can be used to affect the bioavailability of an HGT-1 substrate. Use of HGT-1 fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding an HGT-1 polypeptide; (ii) mis-regulation of the HGT-1 gene; and (iii) aberrant post-translational modification of an HGT-1 polypeptide.

Moreover, the HGT-1-fusion proteins of the invention can be used as immunogens to produce anti-HGT-1 antibodies in a subject, to purify HGT-1 ligands and in screening assays to identify molecules which inhibit the interaction of HGT-1 with an HGT-1 substrate.

Preferably, an HGT-1 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining,

and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, 5 *Current Protocols in Molecular Biology*, eds. Ausubel *et al.*, John Wiley & Sons:1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An HGT-1-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the HGT-1 10 polypeptide.

The present invention also pertains to variants of the HGT-1 polypeptides which function as either HGT-1 agonists (mimetics) or as HGT-1 antagonists. Variants of the HGT-1 polypeptides can be generated by mutagenesis, e.g., discrete point mutation or truncation of an HGT-1 polypeptide. An agonist of the HGT-1 polypeptides can retain 15 substantially the same, or a subset, of the biological activities of the naturally occurring form of an HGT-1 polypeptide. An antagonist of an HGT-1 polypeptide can inhibit one or more of the activities of the naturally occurring form of the HGT-1 polypeptide by, for example, competitively modulating an HGT-1-mediated activity of an HGT-1 polypeptide. Thus, specific biological effects can be elicited by treatment with a variant of limited 20 function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the polypeptide has fewer side effects in a subject relative to treatment with the naturally occurring form of the HGT-1 polypeptide.

In one embodiment, variants of an HGT-1 polypeptide which function as either 25 HGT-1 agonists (mimetics) or as HGT-1 antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of an HGT-1 polypeptide for HGT-1 polypeptide agonist or antagonist activity. In one embodiment, a variegated library of HGT-1 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of HGT-1 variants can be 30 produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential HGT-1 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of HGT-1 sequences therein. There are a variety of methods which can be used to produce libraries of potential HGT-1 variants from a degenerate 35 oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential HGT-1 sequences.

Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acids Res.* 11:477.

In addition, libraries of fragments of an HGT-1 polypeptide coding sequence can be used to generate a variegated population of HGT-1 fragments for screening and subsequent selection of variants of an HGT-1 polypeptide. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an HGT-1 coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the HGT-1 polypeptide.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of HGT-1 polypeptides. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify HGT-1 variants (Arkin and Youvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delagrange *et al.* (1993) *Protein Eng.* 6(3):327-331).

In one embodiment, cell based assays can be exploited to analyze a variegated HGT-1 library. For example, a library of expression vectors can be transfected into a cell line, e.g., an endothelial cell line, which ordinarily responds to HGT-1 in a particular HGT-1 substrate-dependent manner. The transfected cells are then contacted with HGT-1 and the effect of expression of the mutant on signaling by the HGT-1 substrate can be detected, e.g., by monitoring intracellular calcium, IP₃, or diacylglycerol concentration, phosphorylation profile of intracellular proteins, or the activity of an HGT-1-regulated transcription factor. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of signaling by the HGT-1 substrate, and the individual clones further characterized.

An isolated HGT-1 polypeptide, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind HGT-1 using standard techniques for polyclonal and monoclonal antibody preparation. A full-length HGT-1 polypeptide can be used or, alternatively, the invention provides antigenic peptide fragments of HGT-1 for use as immunogens. The antigenic peptide of HGT-1 comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2 and encompasses an epitope of HGT-1 such that an antibody raised against the peptide forms a specific immune complex with HGT-1. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

Preferred epitopes encompassed by the antigenic peptide are regions of HGT-1 that are located on the surface of the polypeptide, *e.g.*, hydrophilic regions, as well as regions with high antigenicity (see, for example, Figure 2).

An HGT-1 immunogen typically is used to prepare antibodies by immunizing a suitable subject (*e.g.*, rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed HGT-1 polypeptide or a chemically synthesized HGT-1 polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic HGT-1 preparation induces a polyclonal anti-HGT-1 antibody response.

Accordingly, another aspect of the invention pertains to anti-HGT-1 antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as HGT-1. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind HGT-1. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of HGT-1. A monoclonal antibody composition thus typically displays a single binding affinity for a particular HGT-1 polypeptide with which it immunoreacts.

Polyclonal anti-HGT-1 antibodies can be prepared as described above by immunizing a suitable subject with an HGT-1 immunogen. The anti-HGT-1 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized HGT-1. If desired, the antibody molecules directed against HGT-1 can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as protein A chromatography to

obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-HGT-1 antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497 (see also, Brown *et al.* (1981) *J. Immunol.* 127:539-46; Brown *et al.* (1980) *J. Biol. Chem.* 255:4980-83; Yeh *et al.* (1976) *Proc. Natl. Acad. Sci. USA* 73:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor *et al.* (1983) *Immunol. Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally Kenneth, R.H. in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); Lerner, E.A. (1981) *Yale J. Biol. Med.* 54:387-402; Gefter, M.L. *et al.* (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an HGT-1 immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds HGT-1.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-HGT-1 monoclonal antibody (see, e.g., Galfre, G. *et al.* (1977) *Nature* 266:55052; Gefter *et al.* (1977) *supra*; Lerner (1981) *supra*; Kenneth (1980) *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind HGT-1, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-HGT-1 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with HGT-1 to thereby isolate immunoglobulin library members that bind HGT-1. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP™ Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner *et al.*, U.S. Patent No. 5,223,409; Kang *et al.*, 5 PCT International Publication No. WO 92/18619; Dower *et al.*, PCT International Publication No. WO 91/17271; Winter *et al.*, PCT International Publication No. WO 10 92/20791; Markland *et al.*, PCT International Publication No. WO 92/15679; Breitling *et al.*, PCT International Publication No. WO 93/01288; McCafferty *et al.*, PCT International Publication No. WO 92/01047; Garrard *et al.*, PCT International Publication No. WO 15 92/09690; Ladner *et al.*, PCT International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Biotechnology (NY)* 9:1369-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J.* 12:725-734; Hawkins *et al.* (1992) *J. Mol. Biol.* 226:889-896; Clackson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580; Garrard *et al.* 20 (1991) *Biotechnology (NY)* 9:1373-1377; Hoogenboom *et al.* (1991) *Nucleic Acids Res.* 19:4133-4137; Barbas *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:7978-7982; and McCafferty *et al.* (1990) *Nature* 348:552-554.

Additionally, recombinant anti-HGT-1 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson *et al.*, International Application No. PCT/US86/02269; Akira *et al.*, European Patent Application No. 184,187; Taniguchi, M., European Patent Application 171,496; Morrison *et al.*, European Patent Application 173,494; Neuberger *et al.*, PCT International Publication No. WO 86/01533; Cabilly *et al.*, U.S. Patent No. 4,816,567; Cabilly *et al.*, European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521-3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Cancer Res.* 47:999-35 1005; Wood *et al.* (1985) *Nature* 314:446-449; and Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559); Morrison, S.L. (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *Biotechniques* 4:214; Winter, U.S. Patent No. 5,225,539; Jones *et al.* (1986) *Nature*

321:552-525; Verhoeyen *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

An anti-HGT-1 antibody (*e.g.*, monoclonal antibody) can be used to isolate HGT-1 by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-
5 HGT-1 antibody can facilitate the purification of natural HGT-1 from cells and of recombinantly produced HGT-1 expressed in host cells. Moreover, an anti-HGT-1 antibody can be used to detect HGT-1 polypeptide (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the HGT-1 polypeptide. Anti-
10 HGT-1 antibodies can be used diagnostically to monitor polypeptide levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish
15 peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of
20 bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, for example recombinant
25 expression vectors, containing a nucleic acid containing an HGT-1 nucleic acid molecule or vectors containing a nucleic acid molecule which encodes an HGT-1 polypeptide (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA
30 segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
35 Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of

plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve 5 equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the 10 nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include 15 promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel (1990) *Methods Enzymol.* 185:3-7. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It 20 will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion 25 proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, HGT-1 polypeptides, mutant forms of HGT-1 polypeptides, fusion proteins, and the like).

Accordingly, an exemplary embodiment provides a method for producing a polypeptide, preferably an HGT-1 polypeptide, by culturing in a suitable medium a host cell of the invention (*e.g.*, a mammalian host cell such as a non-human mammalian cell) containing a recombinant expression vector, such that the polypeptide is produced.

The recombinant expression vectors of the invention can be designed for expression 30 of HGT-1 polypeptides in prokaryotic or eukaryotic cells. For example, HGT-1 polypeptides can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel (1990) *supra*. Alternatively, the recombinant expression 35 vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or

non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be utilized in HGT-1 activity assays (*e.g.*, direct assays or competitive assays described in detail below), or to generate antibodies specific for HGT-1 polypeptides, for example. In a preferred embodiment, an HGT-1 fusion protein expressed in a retroviral expression vector of the present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (*e.g.*, six (6) weeks).

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.* (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.* (1990) *Methods Enzymol.* 185:60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S. (1990) *Methods Enzymol.* 185:119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.* (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the HGT-1 expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYEpSec1 (Baldari *et al.* (1987) *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz (1982) *Cell* 30:933-943),

pJRY88 (Schultz *et al.* (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (Invitrogen Corp, San Diego, CA).

Alternatively, HGT-1 polypeptides can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured 5 insect cells (*e.g.*, Sf 9 cells) include the pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC 10 (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J. *et al.*, *Molecular Cloning: A Laboratory Manual. 2nd ed.*, Cold Spring Harbor Laboratory, Cold Spring 15 Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory 20 elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) 25 *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the 30 murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which 35 allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to HGT-1 mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or

enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of
5 which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which an HGT-1 nucleic acid molecule of the invention is introduced, e.g., an HGT-1 nucleic acid molecule within a vector (e.g., a recombinant expression vector) or an HGT-1 nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
10
15

A host cell can be any prokaryotic or eukaryotic cell. For example, an HGT-1 polypeptide can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.
20

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd ed., Cold Spring Harbor
25
30 Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants,
35 a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same

vector as that encoding an HGT-1 polypeptide or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

5 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) an HGT-1 polypeptide. Accordingly, the invention further provides methods for producing an HGT-1 polypeptide using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention (into which a recombinant expression vector encoding an HGT-1 polypeptide has been
10 introduced) in a suitable medium such that an HGT-1 polypeptide is produced. In another embodiment, the method further comprises isolating an HGT-1 polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which HGT-1-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous HGT-1 sequences have been introduced into their genome or homologous recombinant animals in which endogenous HGT-1 sequences have been altered. Such animals are useful for studying the function and/or activity of an HGT-1 and for identifying and/or evaluating modulators of HGT-1 activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous HGT-1 gene has been altered by homologous recombination between the
20 endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*,
25 which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous HGT-1 gene has been altered by homologous recombination between the
30 endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing an HGT-1-encoding nucleic acid into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The HGT-1 cDNA sequence of SEQ ID NO:1 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of a human HGT-1 gene, such as a mouse or rat HGT-1 gene, can be used as a transgene. Alternatively, an HGT-1 gene homologue, such as another HGT-1 family member, can be isolated based

on hybridization to the HGT-1 cDNA sequences of SEQ ID NO:1 or 3, or the DNA insert of the plasmid deposited with ATCC as Accession Number _____ (described further in subsection I above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the
5 transgene. A tissue-specific regulatory sequence(s) can be operably linked to an HGT-1 transgene to direct expression of an HGT-1 polypeptide to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No.
10 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of an HGT-1 transgene in its genome and/or expression of HGT-1 mRNA in tissues or cells of the animals. A transgenic founder animal can then be
15 used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding an HGT-1 polypeptide can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an HGT-1 gene into which a deletion, addition or substitution has been
20 introduced to thereby alter, *e.g.*, functionally disrupt, the HGT-1 gene. The HGT-1 gene can be a human gene (*e.g.*, the cDNA of SEQ ID NO:3), but more preferably, is a non-human homologue of a human HGT-1 gene (*e.g.*, a cDNA isolated by stringent hybridization with the nucleotide sequence of SEQ ID NO:1). For example, a mouse HGT-1 gene can be used to construct a homologous recombination nucleic acid molecule, *e.g.*, a vector, suitable for
25 altering an endogenous HGT-1 gene in the mouse genome. In a preferred embodiment, the homologous recombination nucleic acid molecule is designed such that, upon homologous recombination, the endogenous HGT-1 gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a “knock out” vector). Alternatively, the homologous recombination nucleic acid molecule can be designed such that, upon
30 homologous recombination, the endogenous HGT-1 gene is mutated or otherwise altered but still encodes functional polypeptide (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous HGT-1 polypeptide). In the homologous recombination nucleic acid molecule, the altered portion of the HGT-1 gene is flanked at its 5' and 3' ends by additional nucleic acid sequence of the HGT-1 gene to allow for
35 homologous recombination to occur between the exogenous HGT-1 gene carried by the homologous recombination nucleic acid molecule and an endogenous HGT-1 gene in a cell, *e.g.*, an embryonic stem cell. The additional flanking HGT-1 nucleic acid sequence is of sufficient length for successful homologous recombination with the endogenous gene.

Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the homologous recombination nucleic acid molecule (see, e.g., Thomas, K.R. and Capecchi, M.R. (1987) *Cell* 51:503 for a description of homologous recombination vectors). The homologous recombination nucleic acid molecule is introduced into a cell, e.g., an
5 embryonic stem cell line (e.g., by electroporation) and cells in which the introduced HGT-1 gene has homologously recombined with the endogenous HGT-1 gene are selected (see e.g., Li, E. et al. (1992) *Cell* 69:915). The selected cells can then be injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in
10 *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, Robertson, E.J., ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring
15 the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination nucleic acid molecules, e.g., vectors, or homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos. WO 90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.

In another embodiment, transgenic non-human animals can be produced which
20 contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355. If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
25

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. (1997) *Nature* 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical
30 pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The
35

offspring borne of this female foster animal will be a clone of the animal from which the cell, *e.g.*, the somatic cell, is isolated.

IV. Pharmaceutical Compositions

5 The HGT-1 nucleic acid molecules, fragments of HGT-1 polypeptides, and anti-HGT-1 antibodies (also referred to herein as “active compounds”) of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, polypeptide, or antibody and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

30 Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example,

glycerol, propylene glycol, and liquid polyethyleneglycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be
5 achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays
10 absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a fragment of an HGT-1 polypeptide or an anti-HGT-1 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution
15 thereof.
20

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared
25 using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
30

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
35

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be

permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are 5 formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect 10 the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be 15 obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage 20 unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and 25 directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Toxicity and therapeutic efficacy of such compounds can be determined by standard 30 pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side 35 effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form
5 employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such
10 information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a polypeptide or antibody can include a single treatment or, preferably, can include a series of treatments.
15
20

In a preferred example, a subject is treated with antibody or polypeptide in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of antibody or polypeptide used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.
25

The present invention encompasses agents which modulate expression or activity.
30 An agent may, for example, be a small molecule. For example, such small molecules include, but are not limited to, peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (*i.e.*, including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds
35 having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds. It is

understood that appropriate doses of small molecule agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of the small molecule will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which
5 the composition is to be administered, if applicable, and the effect which the practitioner desires the small molecule to have upon the nucleic acid or polypeptide of the invention.

Exemplary doses include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (*e.g.*, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per
10 kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. Such appropriate doses may be determined using the assays described herein. When one or more of these small molecules is to be administered to an animal (*e.g.*, a human) in order to
15 modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age,
20 body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

In certain embodiments of the invention, a modulator of HGT-1 activity is administered in combination with other agents (*e.g.*, a small molecule), or in conjunction
25 with another, complementary treatment regime. For example, in one embodiment, a modulator of HGT-1 activity is used to treat a cellular proliferation, growth, differentiation, and/or migration disorder. Accordingly, modulation of HGT-1 activity may be used in conjunction with, for example, another agent or treatment used to treat the disorder, *e.g.*, radiation or conventional chemotherapy.

30 Further, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologues thereof. Therapeutic agents include, but are not limited to, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*,

mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired 10 biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 (“IL-1”), interleukin-2 (“IL-2”), interleukin-6 (“IL-6”), granulocyte 15 macrophage colony stimulating factor (“GM-CSF”), granulocyte colony stimulating factor (“G-CSF”), or other growth factors.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, *e.g.*, Arnon *et al.*, “Monoclonal Antibodies For Immunotargeting of Drugs in Cancer Therapy”, in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld *et al.* (eds.), pp. 243-56 20 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, “Antibodies For Drug Delivery”, in *Controlled Drug Delivery (2nd Ed.)*, Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera *et al.* (eds.), pp. 475-506 (1985); “Analysis, Results, And Future Prospective Of The Therapeutic Use Of 25 Radiolabeled Antibody In Cancer Therapy”, in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin *et al.* (eds.), pp. 303-16 (Academic Press 1985), and Thorpe *et al.*, “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, *Immunol. Rev.* 62:119-58 (1982). Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 30 4,676,980.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent No. 5,328,470) or by stereotactic injection (see *e.g.*, Chen *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The 35 pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be

produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

5

V. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) predictive medicine (*e.g.*, diagnostic assays, prognostic assays, monitoring clinical trials, 10 and pharmacogenetics); and c) methods of treatment (*e.g.*, therapeutic and prophylactic). As described herein, an HGT-1 polypeptide of the invention has one or more of the following activities: (i) it may bind UDP-galactose and N-acetylglucosamine (*e.g.*, N-acetylglucosamine bound to a glycoprotein); (ii) it may catalyze the formation of glycosidic bonds (*e.g.*, between UDP-galactose and N-acetylglucosamine); (iii) it may modulate lactose 15 homeostasis; (iv) it may regulate embryogenesis; (v) it may regulate development; (vi) it may regulate the formation of structural elements of the cell; (vii) it may regulate the metabolism of adhesive ligands; (viii) it may regulate the metabolism of glycoprotein ligands and receptors; (ix) it may regulate blood clotting; (x) it may regulate thrombus dissolution; (xi) it may regulate hormone action; (xii) it may regulate fertilization; (xiii) it 20 may regulate an immune system response; and/or (xiv) it may regulated cellular proliferation, growth, differentiation, and/or migration.

The isolated nucleic acid molecules of the invention can be used, for example, to express HGT-1 polypeptides (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect HGT-1 mRNA (*e.g.*, in a biological sample) or a genetic 25 alteration in an HGT-1 gene, and to modulate HGT-1 activity, as described further below. The HGT-1 polypeptides can be used to treat disorders characterized by insufficient or excessive production of an HGT-1 substrate or production of HGT-1 inhibitors. In addition, the HGT-1 polypeptides can be used to screen for naturally occurring HGT-1 substrates, to screen for drugs or compounds which modulate HGT-1 activity, as well as to treat disorders 30 characterized by insufficient or excessive production of HGT-1 polypeptide or production of HGT-1 polypeptide forms which have decreased, aberrant or unwanted activity compared to HGT-1 wild type polypeptide (*e.g.*, galactosyltransferase associated disorders). Moreover, the anti-HGT-1 antibodies of the invention can be used to detect and isolate HGT-1 polypeptides, to regulate the bioavailability of HGT-1 polypeptides, and modulate HGT-1 35 activity.

A. Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) which bind to HGT-1 polypeptides, have 5 a stimulatory or inhibitory effect on, for example, HGT-1 expression or HGT-1 activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of HGT-1 substrate.

In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of an HGT-1 polypeptide or polypeptide or biologically 10 active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of an HGT-1 polypeptide or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in 15 combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer 20 Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994) *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 25 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), 30 plasmids (Cull *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra*).

In one embodiment, an assay is a cell-based assay in which a cell which expresses an 35 HGT-1 polypeptide or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate HGT-1 activity is determined. Determining the ability of the test compound to modulate HGT-1 activity can be accomplished by monitoring, for example, intracellular or extracellular UDP-galactose,

UMP-galactose, N-acetylglucosamine, or N-acetyllactosamine concentration; glycoprotein synthesis; or cellular growth or proliferation.

The ability of the test compound to modulate HGT-1 binding to a substrate or to bind to HGT-1 can also be determined. Determining the ability of the test compound to modulate HGT-1 binding to a substrate can be accomplished, for example, by coupling the HGT-1 substrate with a radioisotope or enzymatic label such that binding of the HGT-1 substrate to HGT-1 can be determined by detecting the labeled HGT-1 substrate in a complex. Alternatively, HGT-1 could be coupled with a radioisotope or enzymatic label to monitor the ability of a test compound to modulate HGT-1 binding to an HGT-1 substrate in a complex. Determining the ability of the test compound to bind HGT-1 can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to HGT-1 can be determined by detecting the labeled HGT-1 compound in a complex. For example, compounds (*e.g.*, HGT-1 substrates) can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

It is also within the scope of this invention to determine the ability of a compound (*e.g.*, an HGT-1 substrate) to interact with HGT-1 without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a compound with HGT-1 without the labeling of either the compound or the HGT-1.

McConnell, H.M. *et al.* (1992) *Science* 257:1906-1912. As used herein, a "microphysiometer" (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and HGT-1.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing an HGT-1 target molecule (*e.g.*, an HGT-1 substrate) with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the HGT-1 target molecule. Determining the ability of the test compound to modulate the activity of an HGT-1 target molecule can be accomplished, for example, by determining the ability of the HGT-1 polypeptide to bind to or interact with the HGT-1 target molecule.

Determining the ability of the HGT-1 polypeptide, or a biologically active fragment thereof, to bind to or interact with an HGT-1 target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the HGT-1 polypeptide to bind to or interact with an HGT-1 target

molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.*, intracellular Ca^{2+} , diacylglycerol, IP_3 , and the like), detecting catalytic/enzymatic activity of the target using an appropriate substrate,
5 detecting the induction of a reporter gene (comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a target-regulated cellular response.

In yet another embodiment, an assay of the present invention is a cell-free assay in which an HGT-1 polypeptide or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the HGT-1 polypeptide or biologically active portion thereof is determined. Preferred biologically active portions of the HGT-1 polypeptides to be used in assays of the present invention include fragments which participate in interactions with non-HGT-1 molecules, *e.g.*, fragments with high surface probability scores (see, for example, Figure 2). Binding of the test compound to the HGT-1 polypeptide can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the HGT-1 polypeptide or biologically active portion thereof with a known compound which binds HGT-1 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an HGT-1 polypeptide, wherein determining the ability of the test compound to interact with an HGT-1 polypeptide comprises determining the ability of the test compound to preferentially bind to HGT-1 or biologically active portion thereof as compared to the known compound.
10
15
20

In another embodiment, the assay is a cell-free assay in which an HGT-1 polypeptide or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the HGT-1 polypeptide or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of an HGT-1 polypeptide can be accomplished, for example, by determining the ability of the HGT-1 polypeptide to bind to an HGT-1 target molecule by one of the methods described above for determining direct binding.
25
30
35

Determining the ability of the HGT-1 polypeptide to bind to an HGT-1 target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIACore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In an alternative embodiment, determining the ability of the test compound to modulate the activity of an HGT-1 polypeptide can be accomplished by determining the ability of the HGT-1 polypeptide to further modulate the activity of a downstream effector of an HGT-1 target molecule. For example, the activity of the effector molecule on an appropriate target can be determined or the binding of the effector to an appropriate target can be determined as previously described.

In yet another embodiment, the cell-free assay involves contacting an HGT-1 polypeptide or biologically active portion thereof with a known compound which binds the HGT-1 polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the HGT-1 polypeptide, wherein determining the ability of the test compound to interact with the HGT-1 polypeptide comprises determining the ability of the HGT-1 polypeptide to preferentially bind to or modulate the activity of an HGT-1 target molecule.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either HGT-1 or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to an HGT-1 polypeptide, or interaction of an HGT-1 polypeptide with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ HGT-1 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized micrometer plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or HGT-1 polypeptide, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or micrometer plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of HGT-1 binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either an HGT-1 polypeptide or an HGT-1 target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated HGT-1 polypeptide or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well

plates (Pierce Chemical). Alternatively, antibodies reactive with HGT-1 polypeptide or target molecules but which do not interfere with binding of the HGT-1 polypeptide to its target molecule can be derivatized to the wells of the plate, and unbound target or HGT-1 polypeptide trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the HGT-1 polypeptide or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the HGT-1 polypeptide or target molecule.

In another embodiment, modulators of HGT-1 expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of HGT-1 mRNA or polypeptide in the cell is determined. The level of expression of HGT-1 mRNA or polypeptide in the presence of the candidate compound is compared to the level of expression of HGT-1 mRNA or polypeptide in the absence of the candidate compound. The candidate compound can then be identified as a modulator of HGT-1 expression based on this comparison. For example, when expression of HGT-1 mRNA or polypeptide is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of HGT-1 mRNA or polypeptide expression. Alternatively, when expression of HGT-1 mRNA or polypeptide is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of HGT-1 mRNA or polypeptide expression. The level of HGT-1 mRNA or polypeptide expression in the cells can be determined by methods described herein for detecting HGT-1 mRNA or polypeptide.

In yet another aspect of the invention, the HGT-1 polypeptides can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO 94/10300), to identify other proteins, which bind to or interact with HGT-1 (“HGT-1-binding proteins” or “HGT-1-bp”) and are involved in HGT-1 activity. Such HGT-1-binding proteins are also likely to be involved in the propagation of signals by the HGT-1 polypeptides or HGT-1 targets as, for example, downstream elements of an HGT-1-mediated signaling pathway. Alternatively, such HGT-1-binding proteins are likely to be HGT-1 inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for an HGT-1 polypeptide is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that

codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, *in vivo*, forming an HGT-1-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the HGT-1 polypeptide.

In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell free assay, and the ability of the agent to modulate the activity of an HGT-1 polypeptide can be confirmed *in vivo*, *e.g.*, in an animal such as an animal model for cellular transformation and/or tumorigenesis.

For example, the ability of the agent to modulate the activity of a HGT-1 protein can be tested in an animal such as an animal model for a cellular proliferation disorder, *e.g.*, tumorigenesis. Animal based models for studying tumorigenesis *in vivo* are well known in the art (reviewed in *Animal Models of Cancer Predisposition Syndromes*, Hiai, H. and Hino, O. (eds.) 1999, *Progress in Experimental Tumor Research*, Vol. 35; Clarke, A.R. (2000) *Carcinogenesis* 21:435-41) and include, for example, carcinogen-induced tumors (Rithidech, K. *et al.* (1999) *Mutat. Res.* 428:33-39; Miller, M.L. *et al.* (2000) *Environ. Mol. Mutagen.* 35:319-327), injection and/or transplantation of tumor cells into an animal, as well as animals bearing mutations in growth regulatory genes, for example, oncogenes (*e.g.*, ras) (Arbeit, J.M. *et al.* (1993) *Am. J. Pathol.* 142:1187-1197; Sinn, E. *et al.* (1987) *Cell* 49:465-475; Thorgeirsson, SS *et al.* *Toxicol Lett* (2000) 112-113:553-555) and tumor suppressor genes (*e.g.*, p53) (Vooijs, M. *et al.* (1999) *Oncogene* 18:5293-5303; Clark A.R. (1995) *Cancer Metast. Rev.* 14:125-148; Kumar, T.R. *et al.* (1995) *J. Intern. Med.* 238:233-238; Donehower, L.A. *et al.* (1992) *Nature* 356:215-221). Furthermore, experimental model systems are available for the study of, for example, ovarian cancer (Hamilton, T.C. *et al.* (1984) *Semin. Oncol.* 11:285-298; Rahman, N.A. *et al.* (1998) *Mol. Cell. Endocrinol.* 145:167-174; Beamer, W.G. *et al.* (1998) *Toxicol. Pathol.* 26:704-710), gastric cancer (Thompson, J. *et al.* (2000) *Int. J. Cancer* 86:863-869; Fodde, R. *et al.* (1999) *Cytogenet. Cell Genet.* 86:105-111), breast cancer (Li, M. *et al.* (2000) *Oncogene* 19:1010-1019; Green, J.E. *et al.* (2000) *Oncogene* 19:1020-1027), melanoma (Satyamoorthy, K. *et al.* (1999) *Cancer Metast. Rev.* 18:401-405), and prostate cancer (Shirai, T. *et al.* (2000) *Mutat. Res.* 462:219-226; Bostwick, D.G. *et al.* (2000) *Prostate* 43:286-294).

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent

identified as described herein (e.g., an HGT-1 modulating agent, an antisense HGT-1 nucleic acid molecule, an HGT-1-specific antibody, or an HGT-1-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an 5 animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

In another aspect, cell-based systems, as described herein, may be used to identify compounds which may act to ameliorate tumorigenic or proliferative disease symptoms. 10 For example, such cell systems may be exposed to a compound, suspected of exhibiting an ability to ameliorate tumorigenic or proliferative disease symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of tumorigenic or proliferative disease symptoms in the exposed cells. After exposure, the cells are examined to determine whether one or more of the tumorigenic or proliferative disease cellular 15 phenotypes has been altered to resemble a more normal or more wild type, non-tumorigenic disease or non-proliferative disease phenotype. Cellular phenotypes that are associated with tumorigenic disease states include aberrant proliferation and migration, angiogenesis, anchorage-independent growth (i.e., attachment-independent growth), and loss of contact inhibition.

20 In addition, animal-based tumorigenic disease systems, such as those described herein, may be used to identify compounds capable of ameliorating tumorigenic or proliferative disease symptoms. Such animal models may be used as test substrates for the identification of drugs, pharmaceuticals, therapies, and interventions which may be effective in treating tumorigenic or proliferative disease. For example, animal models may be 25 exposed to a compound, suspected of exhibiting an ability to ameliorate tumorigenic or proliferative disease symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of tumorigenic or apoptotic tumorigenic or proliferative disease symptoms in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of disorders associated with tumorigenic disease, for 30 example, by counting the number of tumors and/or measuring their size before and after treatment. In addition, the animals may be monitored by assessing the reversal of disorders associated with tumorigenic disease, for example, reduction in tumor burden, tumor size, and invasive and/or metastatic potential before and after treatment.

With regard to intervention, any treatments which reverse any aspect of tumorigenic 35 or proliferative disease symptoms should be considered as candidates for human tumorigenic or proliferative disease therapeutic intervention. Dosages of test agents may be determined by deriving dose-response curves.

Additionally, gene expression patterns may be utilized to assess the ability of a compound to ameliorate proliferative or tumorigenic disease symptoms. For example, the expression pattern of one or more genes may form part of a "gene expression profile" or "transcriptional profile" which may be then be used in such an assessment. "Gene expression profile" or "transcriptional profile", as used herein, includes the pattern of mRNA expression obtained for a given tissue or cell type under a given set of conditions. Such conditions may include, but are not limited to, the presence of a tumor, *e.g.*, a breast or lung tumor or any of the other tumors described herein, including any of control or experimental conditions described herein.

Other conditions may include, for example, cell differentiation, transformation, metastasis, and carcinogen exposure. Gene expression profiles may be generated, for example, by utilizing a differential display procedure, Northern analysis and/or RT-PCR. In one embodiment, HGT-1 gene sequences may be used as probes and/or PCR primers for the generation and corroboration of such gene expression profiles.

Gene expression profiles may be characterized for known states, either tumorigenic or proliferative disease or normal, within the cell- and/or animal-based model systems. Subsequently, these known gene expression profiles may be compared to ascertain the effect a test compound has to modify such gene expression profiles, and to cause the profile to more closely resemble that of a more desirable profile.

For example, administration of a compound may cause the gene expression profile of a tumorigenic or proliferative disease model system to more closely resemble the control system. Administration of a compound may, alternatively, cause the gene expression profile of a control system to begin to mimic a tumorigenic or proliferative disease state. Such a compound may, for example, be used in further characterizing the compound of interest, or may be used in the generation of additional animal models.

B. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

35

1. Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is

called chromosome mapping. Accordingly, portions or fragments of the HGT-1 nucleotide sequences, described herein, can be used to map the location of the HGT-1 genes on a chromosome. The mapping of the HGT-1 sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

5 Briefly, HGT-1 genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the HGT-1 nucleotide sequences. Computer analysis of the HGT-1 sequences can be used to predict primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human
10 chromosomes. Only those hybrids containing the human gene corresponding to the HGT-1 sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes.
15 By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy
20 mapping of individual genes to specific human chromosomes (D'Eustachio P. *et al.* (1983) *Science* 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the HGT-1 nucleotide sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map an HGT-1 sequence to its chromosome include *in situ* hybridization (described in Fan, Y. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:6223-27), pre-screening with labeled flow-sorted
30 chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in
35 metaphase by a chemical such as colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as

500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma *et al.*,
5 *Human Chromosomes: A Manual of Basic Techniques* (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are
10 more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data (such data are found, for example, in McKusick, V., Mendelian Inheritance in Man, available online through Johns Hopkins University Welch Medical Library). The relationship between a
15 gene and a disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland, J. *et al.* (1987) *Nature* 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and
20 unaffected with a disease associated with the HGT-1 gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome
25 spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

2. Tissue Typing

30 The HGT-1 sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for
35 identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the HGT-1 nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences.

5 These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can

10 be used to obtain such identification sequences from individuals and from tissue. The HGT-1 nucleotide sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between

15 individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO:1 can comfortably

20 provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:3 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from HGT-1 nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be

25 used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

3. Use of HGT-1 Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic biology. Forensic

30 biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, *e.g.*, hair or skin, or body fluids, *e.g.*, blood,

35 saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, *e.g.*, PCR primers, targeted to specific loci in the human genome, which can

enhance the reliability of DNA-based forensic identifications by, for example, providing another “identification marker” (*i.e.*, another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated
5 fragments. Sequences targeted to noncoding regions of SEQ ID NO:1 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the HGT-1 nucleotide sequences or portions thereof, *e.g.*, fragments derived from the noncoding regions of SEQ ID NO:1 having a length of at least
10 20 bases, preferably at least 30 bases.

The HGT-1 nucleotide sequences described herein can further be used to provide polynucleotide reagents, *e.g.*, labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue, *e.g.*, brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown
15 origin. Panels of such HGT-1 probes can be used to identify tissue by species and/or by organ type.

In a similar fashion, these reagents, *e.g.*, HGT-1 primers or probes can be used to screen tissue culture for contamination (*i.e.*, screen for the presence of a mixture of different types of cells in a culture).

20

C. Predictive Medicine:

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one
25 aspect of the present invention relates to diagnostic assays for determining HGT-1 polypeptide and/or nucleic acid expression as well as HGT-1 activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant or unwanted HGT-1 expression or activity (*e.g.*, a cellular
30 proliferation, growth, differentiation, or migration disorder). The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with HGT-1 polypeptide, nucleic acid expression or activity (*e.g.*, a cellular proliferation, growth, differentiation, or migration disorder). For example, mutations in an HGT-1 gene can be assayed in a biological sample. Such assays
35 can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with HGT-1 polypeptide, nucleic acid expression or activity.

Another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of HGT-1 in clinical trials.

These and other agents are described in further detail in the following sections.

5 1. Diagnostic Assays

An exemplary method for detecting the presence or absence of HGT-1 polypeptide or nucleic acid in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting HGT-1 polypeptide or nucleic acid (*e.g.*, mRNA, or genomic DNA) that encodes HGT-1 polypeptide such that the presence of HGT-1 polypeptide or nucleic acid is detected in the biological sample. In another aspect, the present invention provides a method for detecting the presence of HGT-1 activity in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of HGT-1 activity such that the presence of HGT-1 activity is detected in the biological sample. A preferred agent for detecting HGT-1 mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to HGT-1 mRNA or genomic DNA. The nucleic acid probe can be, for example, the HGT-1 nucleic acid set forth in SEQ ID NO:1 or 3, or the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to HGT-1 mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting HGT-1 polypeptide is an antibody capable of binding to HGT-1 polypeptide, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect HGT-1 mRNA, polypeptide, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of HGT-1 mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of HGT-1 polypeptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of HGT-1

genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of HGT-1 polypeptide include introducing into a subject a labeled anti-HGT-1 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

5 The present invention also provides diagnostic assays for identifying the presence or absence of a genetic alteration characterized by at least one of (i) aberrant modification or mutation of a gene encoding an HGT-1 polypeptide; (ii) aberrant expression of a gene encoding an HGT-1 polypeptide; (iii) mis-regulation of the gene; and (iii) aberrant post-translational modification of an HGT-1 polypeptide, wherein a wild-type form of the gene
10 encodes a polypeptide with an HGT-1 activity. “Misexpression or aberrant expression”, as used herein, refers to a non-wild type pattern of gene expression, at the RNA or protein level. It includes, but is not limited to, expression at non-wild type levels (*e.g.*, over or under expression); a pattern of expression that differs from wild type in terms of the time or stage at which the gene is expressed (*e.g.*, increased or decreased expression (as compared
15 with wild type) at a predetermined developmental period or stage); a pattern of expression that differs from wild type in terms of decreased expression (as compared with wild type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild type in terms of the splicing size, amino acid sequence, post-transitional modification, or biological activity of the expressed polypeptide; a pattern of expression that differs from
20 wild type in terms of the effect of an environmental stimulus or extracellular stimulus on expression of the gene (*e.g.*, a pattern of increased or decreased expression (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus).

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test
25 subject or genomic DNA molecules from the test subject. A preferred biological sample is a serum sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting HGT-1 polypeptide, mRNA, or genomic DNA, such that the presence
30 of HGT-1 polypeptide, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of HGT-1 polypeptide, mRNA or genomic DNA in the control sample with the presence of HGT-1 polypeptide, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of HGT-1 in a
35 biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting HGT-1 polypeptide or mRNA in a biological sample; means for determining the amount of HGT-1 in the sample; and means for comparing the amount of HGT-1 in the sample with a standard. The compound or agent can be packaged in a suitable container.

The kit can further comprise instructions for using the kit to detect HGT-1 polypeptide or nucleic acid.

2. Prognostic Assays

5 The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant or unwanted HGT-1 expression or activity (*e.g.*, a cellular proliferation, growth, differentiation, or migration disorder). As used herein, the term “aberrant” includes an HGT-1 expression or activity which deviates from the wild type HGT-1 expression or activity. Aberrant expression or activity includes increased or decreased expression or activity, as well as expression or activity which does not follow the wild type developmental pattern of expression or the subcellular pattern of expression. For example, aberrant HGT-1 expression or activity is intended to include the cases in which a mutation in the HGT-1 gene causes the HGT-1 gene to be under-expressed or over-expressed and situations in
10 which such mutations result in a non-functional HGT-1 polypeptide or a polypeptide which does not function in a wild-type fashion, *e.g.*, a polypeptide which does not interact with an HGT-1 substrate, *e.g.*, a galactosyltransferase subunit or ligand, or one which interacts with a non-HGT-1 substrate, *e.g.*, a non-galactosyltransferase subunit or ligand. As used herein,
15 the term “unwanted” includes an unwanted phenomenon involved in a biological response, such as cellular proliferation. For example, the term unwanted includes an HGT-1 expression or activity which is undesirable in a subject.
20

25 The assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with a misregulation in HGT-1 polypeptide activity or nucleic acid expression, such as a galactosyltransferase disorder, *e.g.*, a cellular proliferation, growth, differentiation, or migration disorder. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disorder associated with a misregulation in HGT-1 polypeptide activity or nucleic acid expression, such as a galactosyltransferase disorder, *e.g.*, a cellular proliferation, growth, differentiation, or migration disorder. Thus, the present
30 invention provides a method for identifying a disease or disorder associated with aberrant or unwanted HGT-1 expression or activity in which a test sample is obtained from a subject and HGT-1 polypeptide or nucleic acid (*e.g.*, mRNA or genomic DNA) is detected, wherein the presence of HGT-1 polypeptide or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant or unwanted HGT-1 expression or activity. As used herein, a “test sample” refers to a biological sample obtained
35 from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant or unwanted HGT-1 expression or activity, e.g., a cellular proliferation, growth, differentiation, or migration disorder. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a galactosyltransferase disorder, e.g., a cellular proliferation, growth, differentiation, or migration disorder. Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant or unwanted HGT-1 expression or activity in which a test sample is obtained and HGT-1 polypeptide or nucleic acid expression or activity is detected (e.g., wherein the abundance of HGT-1 polypeptide or nucleic acid expression or activity is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant or unwanted HGT-1 expression or activity).

The methods of the invention can also be used to detect genetic alterations in an HGT-1 gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by misregulation in HGT-1 polypeptide activity or nucleic acid expression, such as a galactosyltransferase disorder, a lactose homeostasis disorder, or a disorder of cellular growth, differentiation, or migration. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding an HGT-1 -polypeptide, or the mis-expression of the HGT-1 gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from an HGT-1 gene; 2) an addition of one or more nucleotides to an HGT-1 gene; 3) a substitution of one or more nucleotides of an HGT-1 gene, 4) a chromosomal rearrangement of an HGT-1 gene; 5) an alteration in the level of a messenger RNA transcript of an HGT-1 gene, 6) aberrant modification of an HGT-1 gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of an HGT-1 gene, 8) a non-wild type level of an HGT-1-polypeptide, 9) allelic loss of an HGT-1 gene, and 10) inappropriate post-translational modification of an HGT-1-polypeptide. As described herein, there are a large number of assays known in the art which can be used for detecting alterations in an HGT-1 gene. A preferred biological sample is a tissue or serum sample isolated by conventional means from a subject.

In certain embodiments, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.* (1988) *Science* 241:1077-1080; and Nakazawa *et al.* (1994) *Proc.*

Natl. Acad. Sci. USA 91:360-364), the latter of which can be particularly useful for detecting point mutations in the HGT-1-gene (see Abravaya *et al.* (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a subject, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample,

5 contacting the nucleic acid sample with one or more primers which specifically hybridize to an HGT-1 gene under conditions such that hybridization and amplification of the HGT-1-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary

10 amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (Guatelli, J.C. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh, D.Y. *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177),

15 Q-Beta Replicase (Lizardi, P.M. *et al.* (1988) *Bio-Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

20 In an alternative embodiment, mutations in an HGT-1 gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates

25 mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in HGT-1 can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high density arrays containing

30 hundreds or thousands of oligonucleotides probes (Cronin, M.T. *et al.* (1996) *Hum. Mutat.* 7:244-255; Kozal, M.J. *et al.* (1996) *Nat. Med.* 2:753-759). For example, genetic mutations in HGT-1 can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin *et al.* (1996) *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to

35 identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or

mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the HGT-1 gene and detect mutations by comparing the sequence of the sample HGT-1 with the corresponding wild-type (control) sequence.

5 Examples of sequencing reactions include those based on techniques developed by Maxam and Gilbert ((1977) *Proc. Natl. Acad. Sci. USA* 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 10 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.* (1996) *Adv. Chromatogr.* 36:127-162; and Griffin *et al.* (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in the HGT-1 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or 15 RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type HGT-1 sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such 20 as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the 25 mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:4397; Saleeba *et al.* (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

30 In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in HGT-1 cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves 35 T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on an HGT-1 sequence, e.g., a wild-type HGT-1 sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be

detected from electrophoresis protocols or the like. See, for example, U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in HGT-1 genes. For example, single strand conformation polymorphism (SSCP) 5 may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita *et al.* (1989) *Proc Natl. Acad. Sci USA* 86:2766, see also Cotton (1993) *Mutat. Res.* 285:125-144; and Hayashi (1992) *Genet. Anal. Tech. Appl.* 9:73-79). Single-stranded DNA fragments of sample and control HGT-1 nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies 10 according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double 15 stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet* 7:5).

In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as 20 the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

25 Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different 30 mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology which depends on selective 35 PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under

appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini *et al.* (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain embodiments amplification may also be
5 performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-
10 packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an HGT-1 gene.
15

Furthermore, any cell type or tissue in which HGT-1 is expressed may be utilized in
15 the prognostic assays described herein.

3. Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs) on the expression or activity of an HGT-1 polypeptide (*e.g.*, the modulation of galactosyltransferase activity) can be applied
20 not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase HGT-1 gene expression, polypeptide levels, or upregulate HGT-1 activity, can be monitored in clinical trials of subjects exhibiting decreased HGT-1 gene expression, polypeptide levels, or downregulated HGT-1 activity. Alternatively, the effectiveness of an agent determined by a
25 screening assay to decrease HGT-1 gene expression, polypeptide levels, or downregulate HGT-1 activity, can be monitored in clinical trials of subjects exhibiting increased HGT-1 gene expression, polypeptide levels, or upregulated HGT-1 activity. In such clinical trials, the expression or activity of an HGT-1 gene, and preferably, other genes that have been implicated in, for example, an HGT-1-associated disorder can be used as a "read out" or
30 markers of the phenotype of a particular cell.

For example, and not by way of limitation, genes, including HGT-1, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) which modulates HGT-1 activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on HGT-1-associated disorders (*e.g.*,
35 disorders characterized by deregulated signaling or galactosyltransferase activity, *e.g.*, cellular proliferation, growth, differentiation, or migration disorders), for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of HGT-1 and other genes implicated in the HGT-1-associated disorder,

respectively. The levels of gene expression (*e.g.*, a gene expression pattern) can be quantified by northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of polypeptide produced, by one of the methods as described herein, or by measuring the levels of activity of HGT-1 or other genes. In this way, the gene
5 expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist,
10 peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an HGT-1 polypeptide, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the HGT-1 polypeptide, mRNA,
15 or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the HGT-1 polypeptide, mRNA, or genomic DNA in the pre-administration sample with the HGT-1 polypeptide, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject
20 accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of HGT-1 to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of HGT-1 to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent. According to such an embodiment, HGT-1
25 expression or activity may be used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic response.

D. Methods of Treatment:

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant or unwanted HGT-1 expression or activity, *e.g.*, a galactosyltransferase associated disorder (*e.g.*, a cellular proliferation, growth, differentiation, or migration disorder). As used herein, “treatment” of a subject includes the application or administration of a therapeutic agent to a subject, or application or administration of a therapeutic agent to a cell or tissue from a subject, who has a disease or disorder, has a symptom of a disease or disorder, or is at risk of (or susceptible to) a disease or disorder, with the purpose of curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, or affecting the disease or disorder, the symptom of the disease or disorder, or the risk of (or susceptibility to) the disease or

disorder. As used herein, a “therapeutic agent” includes, but is not limited to, small molecules, peptides, polypeptides, antibodies, ribozymes, and antisense oligonucleotides.

With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. “Pharmacogenomics”, as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient’s genes determine his or her response to a drug (*e.g.*, a patient’s “drug response phenotype”, or “drug response genotype”). Thus, another aspect of the invention provides methods for tailoring an individual’s prophylactic or therapeutic treatment with either the HGT-1 molecules of the present invention or HGT-1 modulators according to that individual’s drug response genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

1. Prophylactic Methods

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant or unwanted HGT-1 expression or activity, by administering to the subject an HGT-1 or an agent which modulates HGT-1 expression or at least one HGT-1 activity. Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted HGT-1 expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the HGT-1 aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of HGT-1 aberrancy, for example, an HGT-1, HGT-1 agonist or HGT-1 antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

30 2. Therapeutic Methods

Another aspect of the invention pertains to methods of modulating HGT-1 expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell capable of expressing HGT-1 with an agent that modulates one or more of the activities of HGT-1 polypeptide activity associated with the cell, such that HGT-1 activity in the cell is modulated. An agent that modulates HGT-1 polypeptide activity can be an agent as described herein, such as a nucleic acid or a polypeptide, a naturally-occurring target molecule of an HGT-1 polypeptide (*e.g.*, an HGT-1 substrate), an HGT-1 antibody, an HGT-1 agonist or

antagonist, a peptidomimetic of an HGT-1 agonist or antagonist, or other small molecule. In one embodiment, the agent stimulates one or more HGT-1 activities. Examples of such stimulatory agents include active HGT-1 polypeptide and a nucleic acid molecule encoding HGT-1 that has been introduced into the cell. In another embodiment, the agent inhibits one or more HGT-1 activities. Examples of such inhibitory agents include antisense HGT-1 nucleic acid molecules, anti-HGT-1 antibodies, and HGT-1 inhibitors. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of an HGT-1 polypeptide or nucleic acid molecule, e.g., a cellular proliferation, growth, differentiation, or migration disorder. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) HGT-1 expression or activity. In another embodiment, the method involves administering an HGT-1 polypeptide or nucleic acid molecule as therapy to compensate for reduced, aberrant, or unwanted HGT-1 expression or activity.

Stimulation of HGT-1 activity is desirable in situations in which HGT-1 is abnormally downregulated and/or in which increased HGT-1 activity is likely to have a beneficial effect. Likewise, inhibition of HGT-1 activity is desirable in situations in which HGT-1 is abnormally upregulated and/or in which decreased HGT-1 activity is likely to have a beneficial effect.

3. Pharmacogenomics

The HGT-1 molecules of the present invention, as well as agents, or modulators which have a stimulatory or inhibitory effect on HGT-1 activity (e.g., HGT-1 gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) HGT-1-associated disorders (e.g., cellular proliferation, growth, differentiation, or migration disorders) associated with aberrant or unwanted HGT-1 activity. In conjunction with such treatment, pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer an HGT-1 molecule or HGT-1 modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with an HGT-1 molecule or HGT-1 modulator.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, for example, Eichelbaum, M. *et al.* (1996) *Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 and Linder, M.W. *et al.* (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

One pharmacogenomics approach to identifying genes that predict drug response, known as “a genome-wide association”, relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (*e.g.*, a “bi-allelic” gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two variants). Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a “SNP” is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.

Alternatively, a method termed the “candidate gene approach”, can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drug's target is known (*e.g.*, an HGT-1 polypeptide of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and

cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor 5 metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active 10 therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

15 Alternatively, a method termed the “gene expression profiling”, can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (e.g., an HGT-1 molecule or HGT-1 modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.

Information generated from more than one of the above pharmacogenomics 20 approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an HGT-1 molecule or HGT-1 modulator, such as a modulator identified by one of the exemplary screening assays 25 described herein.

4. Use of HGT-1 Molecules as Surrogate Markers

The HGT-1 molecules of the invention are also useful as markers of disorders or disease states, as markers for precursors of disease states, as markers for predisposition of 30 disease states, as markers of drug activity, or as markers of the pharmacogenomic profile of a subject. Using the methods described herein, the presence, absence and/or quantity of the HGT-1 molecules of the invention may be detected, and may be correlated with one or more biological states *in vivo*. For example, the HGT-1 molecules of the invention may serve as surrogate markers for one or more disorders or disease states or for conditions leading up to 35 disease states. As used herein, a “surrogate marker” is an objective biochemical marker which correlates with the absence or presence of a disease or disorder, or with the progression of a disease or disorder (e.g., with the presence or absence of a tumor). The presence or quantity of such markers is independent of the disease. Therefore, these

markers may serve to indicate whether a particular course of treatment is effective in lessening a disease state or disorder. Surrogate markers are of particular use when the presence or extent of a disease state or disorder is difficult to assess through standard methodologies (e.g., early stage tumors), or when an assessment of disease progression is
5 desired before a potentially dangerous clinical endpoint is reached (e.g., an assessment of cardiovascular disease may be made using cholesterol levels as a surrogate marker, and an analysis of HIV infection may be made using HIV RNA levels as a surrogate marker, well in advance of the undesirable clinical outcomes of myocardial infarction or fully-developed AIDS). Examples of the use of surrogate markers in the art include: Koomen *et al.* (2000)
10 *J. Mass. Spectrom.* 35:258-264; and James (1994) *AIDS Treatment News Archive* 209.

The HGT-1 molecules of the invention are also useful as pharmacodynamic markers. As used herein, a “pharmacodynamic marker” is an objective biochemical marker which correlates specifically with drug effects. The presence or quantity of a pharmacodynamic marker is not related to the disease state or disorder for which the drug is being
15 administered; therefore, the presence or quantity of the marker is indicative of the presence or activity of the drug in a subject. For example, a pharmacodynamic marker may be indicative of the concentration of the drug in a biological tissue, in that the marker is either expressed or transcribed or not expressed or transcribed in that tissue in relationship to the level of the drug. In this fashion, the distribution or uptake of the drug may be monitored by
20 the pharmacodynamic marker. Similarly, the presence or quantity of the pharmacodynamic marker may be related to the presence or quantity of the metabolic product of a drug, such that the presence or quantity of the marker is indicative of the relative breakdown rate of the drug *in vivo*. Pharmacodynamic markers are of particular use in increasing the sensitivity of detection of drug effects, particularly when the drug is administered in low doses. Since
25 even a small amount of a drug may be sufficient to activate multiple rounds of marker (e.g., an HGT-1 marker) transcription or expression, the amplified marker may be in a quantity which is more readily detectable than the drug itself. Also, the marker may be more easily detected due to the nature of the marker itself; for example, using the methods described herein, anti-HGT-1 antibodies may be employed in an immune-based detection system for
30 an HGT-1 polypeptide marker, or HGT-1-specific radiolabeled probes may be used to detect an HGT-1 mRNA marker. Furthermore, the use of a pharmacodynamic marker may offer mechanism-based prediction of risk due to drug treatment beyond the range of possible direct observations. Examples of the use of pharmacodynamic markers in the art include:
35 Matsuda *et al.*, U.S. Patent No. 6,033,862; Hattis *et al.* (1991) *Env. Health Perspect.* 90:229-238; Schentag (1999) *Am. J. Health-Syst. Pharm.* 56 Suppl. 3:S21-S24; and Nicolau (1999) *Am. J. Health-Syst. Pharm.* 56 Suppl. 3:S16-S20.

The HGT-1 molecules of the invention are also useful as pharmacogenomic markers. As used herein, a “pharmacogenomic marker” is an objective biochemical marker which

correlates with a specific clinical drug response or susceptibility in a subject (see, e.g., McLeod *et al.* (1999) *Eur. J. Cancer* 35(12):1650-1652). The presence or quantity of the pharmacogenomic marker is related to the predicted response of the subject to a specific drug or class of drugs prior to administration of the drug. By assessing the presence or 5 quantity of one or more pharmacogenomic markers in a subject, a drug therapy which is most appropriate for the subject, or which is predicted to have a greater degree of success, may be selected. For example, based on the presence or quantity of RNA, or polypeptide (e.g., HGT-1 polypeptide or RNA) for specific tumor markers in a subject, a drug or course 10 of treatment may be selected that is optimized for the treatment of the specific tumor likely to be present in the subject. Similarly, the presence or absence of a specific sequence mutation in HGT-1 DNA may correlate HGT-1 drug response. The use of pharmacogenomic markers therefore permits the application of the most appropriate treatment for each subject without having to administer the therapy.

15 E. Electronic Apparatus Readable Media and Arrays

Electronic apparatus readable media comprising HGT-1 sequence information is also provided. As used herein, "HGT-1 sequence information" refers to any nucleotide and/or amino acid sequence information particular to the HGT-1 molecules of the present invention, including but not limited to full-length nucleotide and/or amino acid sequences, 20 partial nucleotide and/or amino acid sequences, polymorphic sequences including single nucleotide polymorphisms (SNPs), epitope sequences, and the like. Moreover, information "related to" said HGT-1 sequence information includes detection of the presence or absence of a sequence (e.g., detection of expression of a sequence, fragment, polymorphism, etc.), determination of the level of a sequence (e.g., detection of a level of expression, for 25 example, a quantitative detection), detection of a reactivity to a sequence (e.g., detection of protein expression and/or levels, for example, using a sequence-specific antibody), and the like. As used herein, "electronic apparatus readable media" refers to any suitable medium for storing, holding, or containing data or information that can be read and accessed directly by an electronic apparatus. Such media can include, but are not limited to: magnetic 30 storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as compact discs; electronic storage media such as RAM, ROM, EPROM, EEPROM and the like; and general hard disks and hybrids of these categories such as magnetic/optical storage media. The medium is adapted or configured for having recorded thereon HGT-1 sequence information of the present invention.

35 As used herein, the term "electronic apparatus" is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of electronic apparatus suitable for use with the present invention include stand-alone computing apparatuses; networks, including a local area network

(LAN), a wide area network (WAN) Internet, Intranet, and Extranet; electronic appliances such as a personal digital assistants (PDAs), cellular phone, pager and the like; and local and distributed processing systems.

As used herein, "recorded" refers to a process for storing or encoding information on the electronic apparatus readable medium. Those skilled in the art can readily adopt any of the presently known methods for recording information on known media to generate manufactures comprising the HGT-1 sequence information.

A variety of software programs and formats can be used to store the sequence information on the electronic apparatus readable medium. For example, the sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, represented in the form of an ASCII file, or stored in a database application, such as DB2, Sybase, Oracle, or the like, as well as in other forms. Any number of dataprocessor structuring formats (e.g., text file or database) may be employed in order to obtain or create a medium having recorded thereon the HGT-1 sequence information.

By providing HGT-1 sequence information in readable form, one can routinely access the sequence information for a variety of purposes. For example, one skilled in the art can use the sequence information in readable form to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of the sequences of the invention which match a particular target sequence or target motif.

The present invention therefore provides a medium for holding instructions for performing a method for determining whether a subject has a HGT-1 associated disease or disorder or a pre-disposition to a cellular proliferation, growth, differentiation, and/or migration disorder, wherein the method comprises the steps of determining HGT-1 sequence information associated with the subject and based on the HGT-1 sequence information, determining whether the subject has a cellular proliferation, growth, differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation, growth, differentiation, and/or migration disorder, and/or recommending a particular treatment for the disease, disorder, or pre-disease condition.

The present invention further provides in an electronic system and/or in a network, a method for determining whether a subject has a cellular proliferation, growth, differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation, growth, differentiation, and/or migration disorder wherein the method comprises the steps of determining HGT-1 sequence information associated with the subject, and based on the HGT-1 sequence information, determining whether the subject has a cellular proliferation, growth, differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation, growth, differentiation, and/or migration disorder, and/or recommending a

particular treatment for the disease, disorder or pre-disease condition. The method may further comprise the step of receiving phenotypic information associated with the subject and/or acquiring from a network phenotypic information associated with the subject.

The present invention also provides in a network, a method for determining whether
5 a subject has a cellular proliferation, growth, differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation, growth, differentiation, and/or migration disorder associated with HGT-1, said method comprising the steps of receiving HGT-1 sequence information from the subject and/or information related thereto, receiving phenotypic information associated with the subject, acquiring information from the network
10 corresponding to HGT-1 and/or a cellular proliferation, growth, differentiation, and/or migration disorder, and based on one or more of the phenotypic information, the HGT-1 information (e.g., sequence information and/or information related thereto), and the acquired information, determining whether the subject has a cellular proliferation, growth,
differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation,
15 growth, differentiation, and/or migration disorder. The method may further comprise the step of recommending a particular treatment for the disease, disorder or pre-disease condition.

The present invention also provides a business method for determining whether a subject has a cellular proliferation, growth, differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation, growth, differentiation, and/or migration disorder, said method comprising the steps of receiving information related to HGT-1 (e.g., sequence information and/or information related thereto), receiving phenotypic information associated with the subject, acquiring information from the network related to HGT-1 and/or related to a cellular proliferation, growth, differentiation, and/or migration disorder, and based on one
20 or more of the phenotypic information, the HGT-1 information, and the acquired information, determining whether the subject has a cellular proliferation, growth,
differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation,
growth, differentiation, and/or migration disorder. The method may further comprise the
25 step of recommending a particular treatment for the disease, disorder or pre-disease condition.
30

The invention also includes an array comprising a HGT-1 sequence of the present invention. The array can be used to assay expression of one or more genes in the array. In one embodiment, the array can be used to assay gene expression in a tissue to ascertain tissue specificity of genes in the array. In this manner, up to about 7600 genes can be
35 simultaneously assayed for expression, one of which can be HGT-1. This allows a profile to be developed showing a battery of genes specifically expressed in one or more tissues.

In addition to such qualitative determination, the invention allows the quantitation of gene expression. Thus, not only tissue specificity, but also the level of expression of a

battery of genes in the tissue is ascertainable. Thus, genes can be grouped on the basis of their tissue expression *per se* and level of expression in that tissue. This is useful, for example, in ascertaining the relationship of gene expression between or among tissues. Thus, one tissue can be perturbed and the effect on gene expression in a second tissue can be determined. In this context, the effect of one cell type on another cell type in response to a biological stimulus can be determined. Such a determination is useful, for example, to know the effect of cell-cell interaction at the level of gene expression. If an agent is administered therapeutically to treat one cell type but has an undesirable effect on another cell type, the invention provides an assay to determine the molecular basis of the undesirable effect and thus provides the opportunity to co-administer a counteracting agent or otherwise treat the undesired effect. Similarly, even within a single cell type, undesirable biological effects can be determined at the molecular level. Thus, the effects of an agent on expression of other than the target gene can be ascertained and counteracted.

In another embodiment, the array can be used to monitor the time course of expression of one or more genes in the array. This can occur in various biological contexts, as disclosed herein, for example development of a cellular proliferation, growth, differentiation, and/or migration disorder, progression of a cellular proliferation, growth, differentiation, and/or migration disorder, and processes, such a cellular transformation associated with the cellular proliferation, growth, differentiation, and/or migration disorder.

The array is also useful for ascertaining the effect of the expression of a gene on the expression of other genes in the same cell or in different cells (*e.g.*, ascertaining the effect of HGT-1 expression on the expression of other genes). This provides, for example, for a selection of alternate molecular targets for therapeutic intervention if the ultimate or downstream target cannot be regulated.

The array is also useful for ascertaining differential expression patterns of one or more genes in normal and abnormal cells. This provides a battery of genes (*e.g.*, including HGT-1) that could serve as a molecular target for diagnosis or therapeutic intervention.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application, as well as the Figures and the Sequence Listing, are incorporated herein by reference.

EXAMPLES

EXAMPLE 1: IDENTIFICATION AND CHARACTERIZATION OF HUMAN HGT-1 cDNA

5

In this example, the identification and characterization of the gene encoding human HGT-1 (clone 8797) is described.

Isolation of the human HGT-1 cDNA

The invention is based, at least in part, on the discovery of a human gene encoding a novel polypeptide, referred to herein as human HGT-1. The entire sequence of the human clone 8797 was determined and found to contain an open reading frame termed human "HGT-1." The nucleotide sequence of the human HGT-1 gene is set forth in Figures 1A-1C and in the Sequence Listing as SEQ ID NO:1. The amino acid sequence of the human HGT-1 expression product is set forth in Figures 1 and in the Sequence Listing as SEQ ID NO:2. The HGT-1 polypeptide comprises 378 amino acids. The coding region (open reading frame) of SEQ ID NO:1 is set forth as SEQ ID NO:3. Clone 8797, comprising the coding region of human HGT-1, was deposited with the American Type Culture Collection (ATCC[®]), 10801 University Boulevard, Manassas, VA 20110-2209, on _____, and 20 assigned Accession No. _____.

Analysis of the Human HGT-1 Molecules

A search using the polypeptide sequence of SEQ ID NO:2 was performed against the HMM database in PFAM (Figure 3) resulting in the identification of a galactosyltransferase family domain in the amino acid sequence of human HGT-1 at about residues 102-321 of SEQ ID NO:2.

The amino acid sequence of human HGT-1 was analyzed using the program PSORT (available online; see Nakai, K. and Kanehisa, M. (1992) *Genomics* 14:897-911) to predict the localization of the proteins within the cell. This program assesses the presence of 30 different targeting and localization amino acid sequences within the query sequence. The results of this analysis show that human HGT-1 may be localized to the mitochondria, cytoplasm, or Golgi complex, and has a low probability of localization in the vacuole, secretory vesicles, nucleus, and endoplasmic reticulum.

Searches of the amino acid sequence of human HGT-1 were further performed 35 against the Prosite database. These searches resulted in the identification in the amino acid sequence of human HGT-1 of a number of potential N-glycosylation sites, a potential glycosaminoglycan attachment site, a number of potential protein kinase C phosphorylation sites, a number of potential casein kinase II phosphorylation sites, a potential tyrosine kinase

phosphorylation site, a number of potential N-myristoylation sites, and a potential amidation site.

A MEMSAT analysis of the polypeptide sequence of SEQ ID NO:2 was also performed (Figure 4), predicting one transmembrane domain in the amino acid sequence of 5 human HGT-1 (SEQ ID NO:2) at about residues 15-32.

EXAMPLE 2: EXPRESSION OF RECOMBINANT HGT-1 POLYPEPTIDE IN BACTERIAL CELLS

In this example, human HGT-1 is expressed as a recombinant glutathione-S-transferase (GST) fusion polypeptide in *E. coli* and the fusion polypeptide is isolated and characterized. Specifically, HGT-1 is fused to GST and this fusion polypeptide is expressed in *E. coli*, e.g., strain PEB199. Expression of the GST-HGT-1 fusion polypeptide in PEB199 is induced with IPTG. The recombinant fusion polypeptide is purified from crude bacterial lysates of the induced PEB199 strain by affinity chromatography on glutathione beads. Using polyacrylamide gel electrophoretic analysis of the polypeptide purified from the bacterial lysates, the molecular weight of the resultant fusion polypeptide is determined.

EXAMPLE 3: EXPRESSION OF RECOMBINANT HGT-1 POLYPEPTIDE IN COS CELLS

To express the human HGT-1 gene in COS cells, the pcDNA/Amp vector by Invitrogen Corporation (San Diego, CA) is used. This vector contains an SV40 origin of replication, an ampicillin resistance gene, an *E. coli* replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A DNA fragment encoding the entire HGT-1 polypeptide and an HA tag (Wilson *et al.* (1984) *Cell* 37:767) or a FLAG tag fused in-frame to its 3' end of the fragment is cloned into the polylinker region of the vector, thereby placing the expression of the recombinant polypeptide under the control of the CMV promoter.

To construct the plasmid, the human HGT-1 DNA sequence is amplified by PCR using two primers. The 5' primer contains the restriction site of interest followed by 30 approximately twenty nucleotides of the HGT-1 coding sequence starting from the initiation codon; the 3' end sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag or FLAG tag and the last 20 nucleotides of the HGT-1 coding sequence. The PCR amplified fragment and the pCDNA/Amp vector are digested with the appropriate restriction enzymes and the vector is dephosphorylated using 35 the CIAP enzyme (New England Biolabs, Beverly, MA). Preferably the two restriction sites chosen are different so that the HGT-1 gene is inserted in the correct orientation. The ligation mixture is transformed into *E. coli* cells (strains HB101, DH5 α , SURE, available from Stratagene Cloning Systems, La Jolla, CA, can be used), the transformed culture is

plated on ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment.

COS cells are subsequently transfected with the human HGT-1-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-precipitation methods, DEAE-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods for transfecting host cells can be found in Sambrook, J. et al., *Molecular Cloning: A Laboratory Manual*. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The expression of the IC54420 polypeptide is detected by radiolabeling (^{35}S -methionine or ^{35}S -cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D. *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) using an HA specific monoclonal antibody. Briefly, the cells are labeled for 8 hours with ^{35}S -methionine (or ^{35}S -cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated polypeptides are then analyzed by SDS-PAGE.

Alternatively, DNA containing the human HGT-1 coding sequence is cloned directly into the polylinker of the pCDNA/Amp vector using the appropriate restriction sites. The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the HGT-1 polypeptide is detected by radiolabeling and immunoprecipitation using an HGT-1-specific monoclonal antibody.

25 EXAMPLE 4: ANALYSIS OF HUMAN HGT-1 EXPRESSION

This example describes the expression of human HGT-1 mRNA in various tissues, tumors, cell lines, and disease models, as determined using the TaqMan™ procedure and *in situ* hybridization analysis.

30 *In situ* analysis

For *in situ* analysis, various tissues, e.g., tissues obtained from lung or breast, are first frozen on dry ice. Ten-micrometer-thick sections of the tissues are postfixed with 4% formaldehyde in DEPC treated 1X phosphate-buffered saline (PBS) at room temperature for 10 minutes before being rinsed twice in DEPC 1X phosphate-buffered saline and once in 0.1 M triethanolamine-HCl (pH 8.0). Following incubation in 0.25% acetic anhydride-0.1 M triethanolamine-HCl for 10 minutes, sections are rinsed in DEPC 2X SSC (1X SSC is 0.15M NaCl plus 0.015M sodium citrate). Tissues are then dehydrated through a series of

ethanol washes, incubated in 100% chloroform for 5 minutes, and then rinsed in 100% ethanol for 1 minute and 95% ethanol for 1 minute and allowed to air dry.

Hybridizations are performed with ^{35}S -radiolabeled (5×10^7 cpm/ml) cRNA probes. Probes are incubated in the presence of a solution containing 600 mM NaCl, 10 mM Tris (pH 7.5), 1 mM EDTA, 0.01% sheared salmon sperm DNA, 0.01% yeast tRNA, 0.05% yeast total RNA type X1, 1X Denhardt's solution, 50% formamide, 10% dextran sulfate, 100 mM dithiothreitol, 0.1% sodium dodecyl sulfate (SDS), and 0.1% sodium thiosulfate for 18 hours at 55°C.

After hybridization, slides are washed with 2X SSC. Sections were then sequentially incubated at 37°C in TNE (a solution containing 10 mM Tris-HCl (pH 7.6), 500 mM NaCl, and 1 mM EDTA), for 10 minutes, in TNE with 10 µg of RNase A per ml for 30 minutes, and finally in TNE for 10 minutes. Slides are then rinsed with 2X SSC at room temperature, washed with 2X SSC at 50°C for 1 hour, washed with 0.2X SSC at 55°C for 1 hour, and 0.2X SSC at 60°C for 1 hour. Sections are then dehydrated rapidly through serial ethanol-0.3 M sodium acetate concentrations before being air dried and exposed to Kodak Biomax MR scientific imaging film for 24 hours and subsequently dipped in NB-2 photoemulsion and exposed at 4°C for 7 days before being developed and counter stained.

Taqman analysis

The Taqman™ procedure is a quantitative, real-time PCR-based approach to detecting mRNA. The RT-PCR reaction exploits the 5' nuclease activity of AmpliTaq Gold™ DNA Polymerase to cleave a TaqMan™ probe during PCR. Briefly, cDNA was generated from the samples of interest and served as the starting material for PCR amplification. In addition to the 5' and 3' gene-specific primers, a gene-specific oligonucleotide probe (complementary to the region being amplified) was included in the reaction (*i.e.*, the Taqman™ probe). The TaqMan™ probe included an oligonucleotide with a fluorescent reporter dye covalently linked to the 5' end of the probe (such as FAM (6-carboxyfluorescein), TET (6-carboxy-4,7,2',7'-tetrachlorofluorescein), JOE (6-carboxy-4,5-dichloro-2,7-dimethoxyfluorescein), or VIC) and a quencher dye (TAMRA (6-carboxy-N,N,N',N'-tetramethylrhodamine) at the 3' end of the probe.

During the PCR reaction, cleavage of the probe separated the reporter dye and the quencher dye, resulting in increased fluorescence of the reporter. Accumulation of PCR products was detected directly by monitoring the increase in fluorescence of the reporter dye. When the probe was intact, the proximity of the reporter dye to the quencher dye resulted in suppression of the reporter fluorescence. During PCR, if the target of interest was present, the probe specifically annealed between the forward and reverse primer sites. The 5'-3' nucleolytic activity of the AmpliTaq™ Gold DNA Polymerase cleaved the probe between the reporter and the quencher only if the probe hybridized to the target. The probe

fragments were then displaced from the target, and polymerization of the strand continued. The 3' end of the probe was blocked to prevent extension of the probe during PCR. This process occurred in every cycle and did not interfere with the exponential accumulation of product. RNA was prepared using the trizol method and treated with DNase to remove 5 contaminating genomic DNA. cDNA was synthesized using standard techniques. Mock cDNA synthesis in the absence of reverse transcriptase resulted in samples with no detectable PCR amplification of the control GAPDH or β-actin gene confirming efficient removal of genomic DNA contamination.

The expression of human HGT-1 was examined, using Taqman analysis, in various 10 human tumors and normal human tissues. As shown in Figure 5, human HGT-1 was highly expressed in coronary smooth muscle cells, static human umbilical vein endothelial cells (HUVECs), HUVECs under conditions of shear stress, kidney, skeletal muscle, normal brain cortex, prostate epithelial cells, colon tumor, and lung tumor. Figure 5 further indicates that expression of HGT-1 was increased in HUVECs under conditions of shear 15 stress, as compared to static HUVECs; decreased in the heart in congestive heart failure, as compared to normal heart; increased in breast tumor, as compared to normal breast; increased in colon tumor, as compared to normal colon; and increased in lung tumor, as compared to normal lung.

The expression of human HGT-1 was further examined, using Taqman analysis, in 20 various human tumors. As shown in Figure 6, expression of human HGT-1 is increased in 4/6 breast tumors, as compared to normal breast. Human HGT-1 is also increased in 7/7 lung tumors, as compared to normal lung. Human HGT-1 is also increased in 1/4 colon tumors, as compared to normal colon, and in 1/2 colon tumor metastases to the liver, as compared to normal liver or normal colon.

25 The expression of human HGT-1 was further examined, using Taqman analysis, in various lung cancer models. As shown in Figure 7, high expression was observed in H522 adenocarcinoma (AC) cells, H520 squamous cell carcinoma (SCC) cells, H69 small cell lung cancer (SCLC) cells, and H345 (undifferentiated small cell lung cancer) cells.

Finally, the expression of human HGT-1 was examined, using Taqman analysis, in 30 various breast cancer models. As shown in Figure 8, expression of human HGT-1 is induced upon treatment of MCF10A cells with the growth factors EGF or IGF1A. MCF10A cells are immortalized, but otherwise normal cells which grow as attached cells. Expression of human HGT-1 is strongly induced in MCF10AT cells grown in Agar, as 35 compared to MCF10AT cells grown on plastic. MCF10AT cells are pre-malignant cells with the potential for neoplastic progression (MCF10AT cells generate carcinomas in approximately 25% of xenografts). Because only neoplastic cells are capable of losing attachment-dependant growth and growing in agar, increased expression of HGT-1 in MCF10AT cells growing in agar indicates that HGT-1 expression is increased upon

progression from a pre-malignant to a malignant state. Human HGT-1 expression is also increased in MCF10CA (malignant) cells grown in agar, as compared to MCF10CA cells grown on plastic.

5 Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.